PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16000699-11	2005	Maximum amplitudes of ATP-evoked P2X-mediated currents (I(ATP)) were significantly increased for P2X2, P2X(2/6), and P2X5 receptor subtypes after coexpression of ENaC.	PP242	33-36	purinergic receptor P2X, ligand gated ion channel, 2 L homeolog	Xenopus laevis	97-101
18404518-4	2005	Caspase-3 activation and DNA fragmentation in rPCNs induced by the P2X(7)R agonist BzATP were inhibited by the P2X(7)R antagonist oxidized ATP (oATP) or by pre-treatment of cells with P2X(7)R antisense oligonucleotide indicating a direct involvement of the P2X(7)R in nucleotide-induced neuronal cell death.	PP242	67-70	caspase 3	Rattus norvegicus	0-9
12122056-5	2002	Extracellular and whole-cell voltage-clamp recordings in CA3 revealed that bath application of the potent P2X(7) agonist 2",3"-O-(4-benzoylbenzoyl)-ATP (Bz-ATP) caused a long-lasting inhibition of neurotransmission at mossy fiber-CA3 synapses.	PP242	106-109	carbonic anhydrase 3	Rattus norvegicus	57-60
12122056-5	2002	Extracellular and whole-cell voltage-clamp recordings in CA3 revealed that bath application of the potent P2X(7) agonist 2",3"-O-(4-benzoylbenzoyl)-ATP (Bz-ATP) caused a long-lasting inhibition of neurotransmission at mossy fiber-CA3 synapses.	PP242	106-109	carbonic anhydrase 3	Rattus norvegicus	230-233
34731371-0	2022	mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.	PP242	15-20	mechanistic target of rapamycin kinase	Homo sapiens	0-4
33801030-4	2021	A structure-based pharmacophore (SBP) model exploiting the key features of a selective mTOR inhibitor, Torkinib directed at the ATP-binding pocket was generated.	PP242	103-111	mechanistic target of rapamycin kinase	Homo sapiens	87-91
34731371-0	2022	mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.	PP242	15-20	AKT serine/threonine kinase 1	Homo sapiens	78-81
34731371-0	2022	mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.	PP242	15-20	mechanistic target of rapamycin kinase	Homo sapiens	82-86
34731371-9	2022	The mechanism was that PP242 abrogated the promoting effects of SFN on p-p70S6K (Thr389) and p-Akt (Ser473) in ESCC.	PP242	23-28	ribosomal protein S6 kinase B1	Homo sapiens	73-79
34731371-9	2022	The mechanism was that PP242 abrogated the promoting effects of SFN on p-p70S6K (Thr389) and p-Akt (Ser473) in ESCC.	PP242	23-28	AKT serine/threonine kinase 1	Homo sapiens	95-98
34731371-10	2022	CONCLUSIONS: Our findings demonstrate that PP242 enhances the anti-tumor activity of SFN by blocking SFN-induced activation of Akt/mTOR pathway in ESCC, which provides a rationale for treating ESCC using SFN combined with Akt/mTOR pathway inhibitors.	PP242	43-48	AKT serine/threonine kinase 1	Homo sapiens	127-130
34731371-10	2022	CONCLUSIONS: Our findings demonstrate that PP242 enhances the anti-tumor activity of SFN by blocking SFN-induced activation of Akt/mTOR pathway in ESCC, which provides a rationale for treating ESCC using SFN combined with Akt/mTOR pathway inhibitors.	PP242	43-48	mechanistic target of rapamycin kinase	Homo sapiens	131-135
35439535-7	2022	Our results also confirmed that mTOR inhibitor sensitized senolytic cell death is apoptotic and pan-mTOR inhibitors PP242 and AZD8055 works more effectively than mTORC1 inhibitor Rapamycin.	PP242	116-121	Megator	Drosophila melanogaster	32-36
34911836-7	2021	After treatment with mTOR inhibitor PP242, the expression of LC3-II was detected by Western blotting.	PP242	36-41	mechanistic target of rapamycin kinase	Homo sapiens	21-25
34911836-7	2021	After treatment with mTOR inhibitor PP242, the expression of LC3-II was detected by Western blotting.	PP242	36-41	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	61-64
34911836-8	2021	Total RNAs of 3 cases of RA-FLSs before and after treatment with mTOR inhibitor PP242 were extracted by TRIzol and screened by Agilent Human ceRNA Microarray 2019 (4x180 K, design ID: 086188) chip.	PP242	80-85	mechanistic target of rapamycin kinase	Homo sapiens	65-69
34911836-13	2021	After 6 RA-FLSs were treated with PP242, the expression level of autophagy marker protein LC3-II was increased (P<0.05).	PP242	34-39	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	90-93
34532116-0	2021	A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer.	PP242	37-42	epidermal growth factor receptor	Homo sapiens	92-96
34532116-3	2021	Methods: Here we combined the anti-EGFR monoclonal antibody cetuximab (CTX) with the mTOR inhibitor PP242 in CRC cell lines and mouse xenograft models and discussed the changes of EGFR downstream signaling pathways of CRC cell lines.	PP242	100-105	epidermal growth factor receptor	Mus musculus	35-39
34532116-3	2021	Methods: Here we combined the anti-EGFR monoclonal antibody cetuximab (CTX) with the mTOR inhibitor PP242 in CRC cell lines and mouse xenograft models and discussed the changes of EGFR downstream signaling pathways of CRC cell lines.	PP242	100-105	mechanistic target of rapamycin kinase	Mus musculus	85-89
34532116-5	2021	In BRAF wild-type Caco-2 cells, combined application of CTX and PP242 inhibited the activation of the EGFR and its downstream signaling pathways.	PP242	64-69	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	3-7
34532116-5	2021	In BRAF wild-type Caco-2 cells, combined application of CTX and PP242 inhibited the activation of the EGFR and its downstream signaling pathways.	PP242	64-69	epidermal growth factor receptor	Homo sapiens	102-106
34532116-7	2021	We revealed that the combined application of CTX and PP242 can inhibit tumor growth and proliferation by inhibiting the phosphorylation of key molecules in EGFR downstream MEK-ERK and MEK 4/7 (MKK)-c-Jun N-terminal kinase (JNK) signaling pathways in BRAF wild-type CRC cells.	PP242	53-58	epidermal growth factor receptor	Mus musculus	156-160
34532116-7	2021	We revealed that the combined application of CTX and PP242 can inhibit tumor growth and proliferation by inhibiting the phosphorylation of key molecules in EGFR downstream MEK-ERK and MEK 4/7 (MKK)-c-Jun N-terminal kinase (JNK) signaling pathways in BRAF wild-type CRC cells.	PP242	53-58	midkine	Mus musculus	172-175
34532116-7	2021	We revealed that the combined application of CTX and PP242 can inhibit tumor growth and proliferation by inhibiting the phosphorylation of key molecules in EGFR downstream MEK-ERK and MEK 4/7 (MKK)-c-Jun N-terminal kinase (JNK) signaling pathways in BRAF wild-type CRC cells.	PP242	53-58	mitogen-activated protein kinase 1	Mus musculus	176-179
34532116-7	2021	We revealed that the combined application of CTX and PP242 can inhibit tumor growth and proliferation by inhibiting the phosphorylation of key molecules in EGFR downstream MEK-ERK and MEK 4/7 (MKK)-c-Jun N-terminal kinase (JNK) signaling pathways in BRAF wild-type CRC cells.	PP242	53-58	mitogen-activated protein kinase kinase 4	Homo sapiens	184-191
34532116-7	2021	We revealed that the combined application of CTX and PP242 can inhibit tumor growth and proliferation by inhibiting the phosphorylation of key molecules in EGFR downstream MEK-ERK and MEK 4/7 (MKK)-c-Jun N-terminal kinase (JNK) signaling pathways in BRAF wild-type CRC cells.	PP242	53-58	mitogen-activated protein kinase 8	Homo sapiens	223-226
34532116-7	2021	We revealed that the combined application of CTX and PP242 can inhibit tumor growth and proliferation by inhibiting the phosphorylation of key molecules in EGFR downstream MEK-ERK and MEK 4/7 (MKK)-c-Jun N-terminal kinase (JNK) signaling pathways in BRAF wild-type CRC cells.	PP242	53-58	Braf transforming gene	Mus musculus	250-254
34532116-8	2021	In addition, we found that in BRAF mutant CRC cells, the monotherapy of PP242 resulted in negative feedback increased EGFR phosphorylation rates, accompanied by significant up-regulation of downstream MEK and ERK phosphorylation.	PP242	72-77	Braf transforming gene	Mus musculus	30-34
34532116-8	2021	In addition, we found that in BRAF mutant CRC cells, the monotherapy of PP242 resulted in negative feedback increased EGFR phosphorylation rates, accompanied by significant up-regulation of downstream MEK and ERK phosphorylation.	PP242	72-77	epidermal growth factor receptor	Mus musculus	118-122
34532116-8	2021	In addition, we found that in BRAF mutant CRC cells, the monotherapy of PP242 resulted in negative feedback increased EGFR phosphorylation rates, accompanied by significant up-regulation of downstream MEK and ERK phosphorylation.	PP242	72-77	midkine	Mus musculus	201-204
34532116-8	2021	In addition, we found that in BRAF mutant CRC cells, the monotherapy of PP242 resulted in negative feedback increased EGFR phosphorylation rates, accompanied by significant up-regulation of downstream MEK and ERK phosphorylation.	PP242	72-77	mitogen-activated protein kinase 1	Mus musculus	209-212
34073791-4	2021	Second-generation inhibitor, pp242, inhibits both mTORC1 and mtORC2, which led us to explore its therapeutic potential after SCI and compare it to RAPA treatment.	PP242	29-34	CREB regulated transcription coactivator 1	Mus musculus	50-56
34073791-4	2021	Second-generation inhibitor, pp242, inhibits both mTORC1 and mtORC2, which led us to explore its therapeutic potential after SCI and compare it to RAPA treatment.	PP242	29-34	CREB regulated transcription coactivator 2	Mus musculus	61-67
34073791-9	2021	These results suggest that dual mTOR inhibition by pp242 after SCI induces distinct mechanisms and leads to recovery somewhat inferior to that following RAPA treatment.	PP242	51-56	mechanistic target of rapamycin kinase	Rattus norvegicus	32-36
35439535-7	2022	Our results also confirmed that mTOR inhibitor sensitized senolytic cell death is apoptotic and pan-mTOR inhibitors PP242 and AZD8055 works more effectively than mTORC1 inhibitor Rapamycin.	PP242	116-121	Megator	Drosophila melanogaster	100-104
32861759-13	2020	Meanwhile, PFOS-mediated lysosomal function and the inhibitory effect of autophagic flux could be reversed by PP242 at 40 nM concentration, an mTOR inhibitor.	PP242	110-115	mechanistic target of rapamycin kinase	Homo sapiens	143-147
35472745-6	2022	Thus, the bromodomain inhibitor RVX-208 significantly augmented the therapeutic effects of the dual mTORC1/2 inhibitors, OSI-027 and PP242, both in vitro and in a human xenograft murine model.	PP242	133-138	CREB regulated transcription coactivator 2	Mus musculus	100-108
33790341-4	2021	PP242, an inhibitor of mTORC1/2 pathways exhibits potent natriuretic actions and completely prevented salt-induced hypertension in SS rats.	PP242	0-5	CREB regulated transcription coactivator 2	Mus musculus	23-31
33790341-8	2021	These responses were almost completely abolished by pretreatment of mTAL with 10 microM PP242, indicating that mTORC1/2 pathways were involved in the H2O2 induced increase of [Na+]i. mTAL cell volume remained unchanged (+- 1%) by H2O2 as determined by 3D reconstruction confocal laser scanning microscopy techniques.	PP242	88-93	CREB regulated transcription coactivator 2	Mus musculus	111-119
33790341-9	2021	Consistent with the microscopy data, Western Blot analysis of proteins obtained from freshly isolated mTAL treated with 100 microM H2O2 exhibited increased activity/phosphorylation of AKT (pAKTSer473/AKT) that was inhibited by PP242.	PP242	227-232	AKT serine/threonine kinase 1	Rattus norvegicus	184-187
33790341-9	2021	Consistent with the microscopy data, Western Blot analysis of proteins obtained from freshly isolated mTAL treated with 100 microM H2O2 exhibited increased activity/phosphorylation of AKT (pAKTSer473/AKT) that was inhibited by PP242.	PP242	227-232	AKT serine/threonine kinase 1	Rattus norvegicus	190-193
32990653-7	2020	Results: V-ATPase activity in PTs was markedly enhanced by insulin, and its activation was completely inhibited by bafilomycin (a V-ATPase-specific inhibitor), Akt inhibitor VIII, and PP242 (an mTORC1/2 inhibitor), but not by rapamycin (an mTORC1 inhibitor).	PP242	184-189	ATPase, H+ transporting, lysosomal V0 subunit D2	Mus musculus	9-17
33067464-1	2020	PP242, an inhibitor of mechanistic target of rapamycin (mTOR), displays potent anticancer effects against various cancer types.	PP242	0-5	mechanistic target of rapamycin kinase	Mus musculus	23-54
33067464-1	2020	PP242, an inhibitor of mechanistic target of rapamycin (mTOR), displays potent anticancer effects against various cancer types.	PP242	0-5	mechanistic target of rapamycin kinase	Mus musculus	56-60
33067464-8	2020	This study reveals new insights into the underlying anticancer mechanism of the dual mTOR inhibitor PP242, and could help further to facilitate the understanding of PP242 effects in the clinical application.	PP242	100-105	mechanistic target of rapamycin kinase	Mus musculus	85-89
33067464-8	2020	This study reveals new insights into the underlying anticancer mechanism of the dual mTOR inhibitor PP242, and could help further to facilitate the understanding of PP242 effects in the clinical application.	PP242	165-170	mechanistic target of rapamycin kinase	Mus musculus	85-89
32990653-7	2020	Results: V-ATPase activity in PTs was markedly enhanced by insulin, and its activation was completely inhibited by bafilomycin (a V-ATPase-specific inhibitor), Akt inhibitor VIII, and PP242 (an mTORC1/2 inhibitor), but not by rapamycin (an mTORC1 inhibitor).	PP242	184-189	ATPase, H+ transporting, lysosomal V0 subunit D2	Mus musculus	130-138
32990653-7	2020	Results: V-ATPase activity in PTs was markedly enhanced by insulin, and its activation was completely inhibited by bafilomycin (a V-ATPase-specific inhibitor), Akt inhibitor VIII, and PP242 (an mTORC1/2 inhibitor), but not by rapamycin (an mTORC1 inhibitor).	PP242	184-189	CREB regulated transcription coactivator 2	Mus musculus	194-202
32990653-7	2020	Results: V-ATPase activity in PTs was markedly enhanced by insulin, and its activation was completely inhibited by bafilomycin (a V-ATPase-specific inhibitor), Akt inhibitor VIII, and PP242 (an mTORC1/2 inhibitor), but not by rapamycin (an mTORC1 inhibitor).	PP242	184-189	CREB regulated transcription coactivator 1	Mus musculus	194-200
32990653-9	2020	PP242 completely suppressed the insulin-mediated V-ATPase stimulation in mouse PTs, whereas rapamycin failed to influence the effect of insulin.	PP242	0-5	ATPase, H+ transporting, lysosomal V0 subunit D2	Mus musculus	49-57
32990653-10	2020	Insulin-induced Akt phosphorylation in the mouse renal cortex was completely suppressed by Akt1/2 inhibitor VIII and PP242, but not by rapamycin.	PP242	117-122	thymoma viral proto-oncogene 1	Mus musculus	16-19
32642408-4	2020	Furthermore, we found that mTORC1/ mTORC2 inhibitor PP242 exhibited more efficacious anti-proliferative effect on ESCC cells than mTORC1 inhibitor RAD001 due to RAD001-triggered feedback activation of AKT signal.	PP242	52-57	CREB regulated transcription coactivator 1	Mus musculus	27-33
32512069-11	2020	The mTOR inhibitor PP242 ameliorated Cu(II)-impaired TFEB expression, lysosomal biogenesis, autophagic flux, and Abetao clearance in microglia.	PP242	19-24	mechanistic target of rapamycin kinase	Homo sapiens	4-8
32512069-11	2020	The mTOR inhibitor PP242 ameliorated Cu(II)-impaired TFEB expression, lysosomal biogenesis, autophagic flux, and Abetao clearance in microglia.	PP242	19-24	transcription factor EB	Homo sapiens	53-57
32642408-4	2020	Furthermore, we found that mTORC1/ mTORC2 inhibitor PP242 exhibited more efficacious anti-proliferative effect on ESCC cells than mTORC1 inhibitor RAD001 due to RAD001-triggered feedback activation of AKT signal.	PP242	52-57	CREB regulated transcription coactivator 2	Mus musculus	35-41
32642408-4	2020	Furthermore, we found that mTORC1/ mTORC2 inhibitor PP242 exhibited more efficacious anti-proliferative effect on ESCC cells than mTORC1 inhibitor RAD001 due to RAD001-triggered feedback activation of AKT signal.	PP242	52-57	AKT serine/threonine kinase 1	Homo sapiens	201-204
32642408-6	2020	Noteworthy, knocking-down stably RICTOR significantly suppresses RAD001-induced feedback activation of AKT/PRAS40 signaling, and enhances inhibition efficacy of PP242 on the phosphorylation of AKT and PRAS40, thus potentiates the antitumor effect of RAD001 and PP242 both in vitro and in vivo.	PP242	161-166	RPTOR independent companion of MTOR complex 2	Homo sapiens	33-39
32642408-6	2020	Noteworthy, knocking-down stably RICTOR significantly suppresses RAD001-induced feedback activation of AKT/PRAS40 signaling, and enhances inhibition efficacy of PP242 on the phosphorylation of AKT and PRAS40, thus potentiates the antitumor effect of RAD001 and PP242 both in vitro and in vivo.	PP242	161-166	AKT serine/threonine kinase 1	Homo sapiens	193-196
32642408-6	2020	Noteworthy, knocking-down stably RICTOR significantly suppresses RAD001-induced feedback activation of AKT/PRAS40 signaling, and enhances inhibition efficacy of PP242 on the phosphorylation of AKT and PRAS40, thus potentiates the antitumor effect of RAD001 and PP242 both in vitro and in vivo.	PP242	161-166	AKT1 substrate 1	Homo sapiens	201-207
32642408-6	2020	Noteworthy, knocking-down stably RICTOR significantly suppresses RAD001-induced feedback activation of AKT/PRAS40 signaling, and enhances inhibition efficacy of PP242 on the phosphorylation of AKT and PRAS40, thus potentiates the antitumor effect of RAD001 and PP242 both in vitro and in vivo.	PP242	261-266	RPTOR independent companion of MTOR complex 2	Homo sapiens	33-39
31732667-2	2019	Here we demonstrate that dual mTORC1/mTORC2 inhibitors OSI-027 and PP242 cause catastrophic macropinocytosis in rhabdomyosarcoma (RMS) cells and cancers of the skin, breast, lung, and cervix, whereas the effects are much less pronounced in immortalized human keratinocytes.	PP242	67-72	CREB regulated transcription coactivator 1	Mus musculus	30-36
32062191-7	2020	Interestingly, PP242 (mTORC1/2 inhibitor) or Akt inhibitor X, like rapamycin (mTORC1 inhibitor), reduced the basal or hsBAFF-induced [Ca2+]i elevations.	PP242	15-20	CREB regulated transcription coactivator 1	Mus musculus	22-28
31806641-3	2020	Here, we tested three distinct mTOR kinase inhibitors (TORKi) PP242, KU-0063794, and sapanisertib against glioblastoma cells.	PP242	62-67	mechanistic target of rapamycin kinase	Homo sapiens	31-35
31806641-5	2020	Apoptosis induced by PP242 resulted from off-target cooperative inhibition of JAK2 and protein kinase C alpha (PKCalpha).	PP242	21-26	Janus kinase 2	Homo sapiens	78-82
31806641-5	2020	Apoptosis induced by PP242 resulted from off-target cooperative inhibition of JAK2 and protein kinase C alpha (PKCalpha).	PP242	21-26	protein kinase C alpha	Homo sapiens	87-109
31806641-5	2020	Apoptosis induced by PP242 resulted from off-target cooperative inhibition of JAK2 and protein kinase C alpha (PKCalpha).	PP242	21-26	protein kinase C alpha	Homo sapiens	111-119
31732667-2	2019	Here we demonstrate that dual mTORC1/mTORC2 inhibitors OSI-027 and PP242 cause catastrophic macropinocytosis in rhabdomyosarcoma (RMS) cells and cancers of the skin, breast, lung, and cervix, whereas the effects are much less pronounced in immortalized human keratinocytes.	PP242	67-72	CREB regulated transcription coactivator 2	Mus musculus	37-43
30993706-10	2019	In addition, PP242, an mTOR inhibitor, induced mRNA expression of Muc1, miRNA200a, and miRNa223-3p whereas it declined the expression of LIF.	PP242	13-18	mechanistic target of rapamycin kinase	Homo sapiens	23-27
31771139-8	2019	Treatment with pan-mTOR inhibitor PP242 diminishes DNA damage-induced gammaH2AX and BRCA1 foci formation.	PP242	34-39	mechanistic target of rapamycin kinase	Homo sapiens	19-23
31771139-8	2019	Treatment with pan-mTOR inhibitor PP242 diminishes DNA damage-induced gammaH2AX and BRCA1 foci formation.	PP242	34-39	BRCA1 DNA repair associated	Homo sapiens	84-89
30968418-11	2019	The PP242-treated group demonstrated a significant rise in the expression of MUC1, miRNA 223-3p and a remarkable decline in ERK1/2 and p-4E-BP1 levels in comparison with the control group.	PP242	4-9	mucin 1, transmembrane	Mus musculus	77-81
30968418-11	2019	The PP242-treated group demonstrated a significant rise in the expression of MUC1, miRNA 223-3p and a remarkable decline in ERK1/2 and p-4E-BP1 levels in comparison with the control group.	PP242	4-9	mitogen-activated protein kinase 3	Mus musculus	124-130
30993706-10	2019	In addition, PP242, an mTOR inhibitor, induced mRNA expression of Muc1, miRNA200a, and miRNa223-3p whereas it declined the expression of LIF.	PP242	13-18	mucin 1, transmembrane	Mus musculus	66-70
30968418-11	2019	The PP242-treated group demonstrated a significant rise in the expression of MUC1, miRNA 223-3p and a remarkable decline in ERK1/2 and p-4E-BP1 levels in comparison with the control group.	PP242	4-9	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	137-143
30993706-10	2019	In addition, PP242, an mTOR inhibitor, induced mRNA expression of Muc1, miRNA200a, and miRNa223-3p whereas it declined the expression of LIF.	PP242	13-18	leukemia inhibitory factor	Mus musculus	137-140
30968418-12	2019	Combination therapy of (FCA+PP242) resulted in a remarkable rise in LIF, Msx-1, HB-EGF, ERK1/2, and mTOR levels, in comparison with the PP242 group.	PP242	28-33	leukemia inhibitory factor	Mus musculus	68-71
30993706-11	2019	Moreover, activity of the ERK1/2-mTOR pathway in the endometrial cells was deterred by dexamethasone and PP242.	PP242	105-110	mitogen-activated protein kinase 3	Homo sapiens	26-32
30993706-11	2019	Moreover, activity of the ERK1/2-mTOR pathway in the endometrial cells was deterred by dexamethasone and PP242.	PP242	105-110	mechanistic target of rapamycin kinase	Homo sapiens	33-37
30968418-12	2019	Combination therapy of (FCA+PP242) resulted in a remarkable rise in LIF, Msx-1, HB-EGF, ERK1/2, and mTOR levels, in comparison with the PP242 group.	PP242	28-33	msh homeobox 1	Mus musculus	73-78
31065010-5	2019	Torin, PP242, and a PKCzeta inhibitory peptide, but not rapamycin, prevented these biliverdin-induced responses and TLR4 inhibition.	PP242	7-12	toll like receptor 4	Homo sapiens	116-120
30968418-12	2019	Combination therapy of (FCA+PP242) resulted in a remarkable rise in LIF, Msx-1, HB-EGF, ERK1/2, and mTOR levels, in comparison with the PP242 group.	PP242	28-33	heparin-binding EGF-like growth factor	Mus musculus	80-86
30968418-12	2019	Combination therapy of (FCA+PP242) resulted in a remarkable rise in LIF, Msx-1, HB-EGF, ERK1/2, and mTOR levels, in comparison with the PP242 group.	PP242	28-33	mitogen-activated protein kinase 3	Mus musculus	88-94
30968418-12	2019	Combination therapy of (FCA+PP242) resulted in a remarkable rise in LIF, Msx-1, HB-EGF, ERK1/2, and mTOR levels, in comparison with the PP242 group.	PP242	28-33	mechanistic target of rapamycin kinase	Mus musculus	100-104
30968418-13	2019	Furthermore, combination therapy of (FCA+PP242) downregulated the expression of MUC1 in comparison with the PP242-treated group.	PP242	41-46	mucin 1, transmembrane	Mus musculus	80-84
30968418-13	2019	Furthermore, combination therapy of (FCA+PP242) downregulated the expression of MUC1 in comparison with the PP242-treated group.	PP242	108-113	mucin 1, transmembrane	Mus musculus	80-84
31473880-10	2019	The PRMT5 inhibitor EPZ015666 displayed synergistic anti-GBM effects in vitro and in a xenograft mouse model in combination with PP242.	PP242	129-134	protein arginine N-methyltransferase 5	Mus musculus	4-9
31081172-12	2019	However, the administration of mTORC1/2 inhibitor PP242 could recover the phosphorylation of S6K1, which suggested that mTORC2 was involved in the regulation of mTORC1 activity.	PP242	50-55	CREB regulated transcription coactivator 1	Mus musculus	31-37
31081172-12	2019	However, the administration of mTORC1/2 inhibitor PP242 could recover the phosphorylation of S6K1, which suggested that mTORC2 was involved in the regulation of mTORC1 activity.	PP242	50-55	ribosomal protein S6 kinase B1	Homo sapiens	93-97
31081172-12	2019	However, the administration of mTORC1/2 inhibitor PP242 could recover the phosphorylation of S6K1, which suggested that mTORC2 was involved in the regulation of mTORC1 activity.	PP242	50-55	CREB regulated transcription coactivator 2	Mus musculus	120-126
31081172-12	2019	However, the administration of mTORC1/2 inhibitor PP242 could recover the phosphorylation of S6K1, which suggested that mTORC2 was involved in the regulation of mTORC1 activity.	PP242	50-55	CREB regulated transcription coactivator 1	Mus musculus	161-167
30300823-3	2018	In this study, we investigated whether an mTORC1/2 kinase inhibitor, PP242, which was reported to activate lysosomal function, potentiates the cytotoxicity of GO in AML cells.	PP242	69-74	CREB regulated transcription coactivator 1	Mus musculus	42-48
30075169-5	2019	Pre-incubation of DR slices with the mTOR inhibitor PP242 decreased the frequency of sEPSCs and prevented the effect of ketamine.	PP242	52-57	mechanistic target of rapamycin kinase	Homo sapiens	37-41
30482887-7	2018	The pp242-treated cells survive due to formation of the non-autophagous LC3-negative vacuoles, which contain the damaged mitochondria and lysosomes with the following excretion the content from the cell.	PP242	4-9	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	72-75
30346178-2	2018	By reference to the crystal structure of mTOR-PP242, we explored to discover potential ATP-competitive inhibitors of mTOR.	PP242	46-51	mechanistic target of rapamycin kinase	Homo sapiens	41-45
30346178-2	2018	By reference to the crystal structure of mTOR-PP242, we explored to discover potential ATP-competitive inhibitors of mTOR.	PP242	46-51	mechanistic target of rapamycin kinase	Homo sapiens	117-121
30300823-7	2018	LysoTracker fluorescence was dramatically increased by treatment with PP242 in U937, THP-1 and SKM-1 cells, and the intensified fluorescence was retained with PP242 + GO.	PP242	70-75	GLI family zinc finger 2	Homo sapiens	85-90
30300823-7	2018	LysoTracker fluorescence was dramatically increased by treatment with PP242 in U937, THP-1 and SKM-1 cells, and the intensified fluorescence was retained with PP242 + GO.	PP242	70-75	sodium voltage-gated channel alpha subunit 4	Homo sapiens	95-100
30300823-10	2018	Further, PP242 suppressed GO-induced Chk1 activation and G2/M cell cycle arrest, which in turn triggered cell cycle promotion and cell death.	PP242	9-14	checkpoint kinase 1	Homo sapiens	37-41
30300823-11	2018	These results indicate that inhibition of mTORC1/2 kinase by PP242 enhanced the cytotoxicity of GO by increasing lysosomal compartments and promoting the cell cycle via suppression of GO-induced Chk1 activation.	PP242	61-66	CREB regulated transcription coactivator 1	Mus musculus	42-48
30300823-11	2018	These results indicate that inhibition of mTORC1/2 kinase by PP242 enhanced the cytotoxicity of GO by increasing lysosomal compartments and promoting the cell cycle via suppression of GO-induced Chk1 activation.	PP242	61-66	checkpoint kinase 1	Homo sapiens	195-199
30356017-1	2018	We previously reported that PP242 (dual inhibitor of mTORC1/2) plus curcumin induced apoptotic cell death through lysosomal membrane permeabilization (LMP)-mediated autophagy.	PP242	28-33	CREB regulated transcription coactivator 2	Mus musculus	53-61
30356017-6	2018	Furthermore, overexpression of HSP70 significantly inhibited PP242 plus curcumin-induced LMP and apoptosis, but the protective effect was abolished by K77R mutation of acetylation site of HSP70.	PP242	61-66	heat shock protein family A (Hsp70) member 4	Homo sapiens	31-36
30356017-6	2018	Furthermore, overexpression of HSP70 significantly inhibited PP242 plus curcumin-induced LMP and apoptosis, but the protective effect was abolished by K77R mutation of acetylation site of HSP70.	PP242	61-66	heat shock protein family A (Hsp70) member 4	Homo sapiens	188-193
30356017-7	2018	Taken together, our results reveal that regulation of HSP70 through K77 acetylation plays role in combined PP242 and curcumin treatment-induced apoptosis.	PP242	107-112	heat shock protein family A (Hsp70) member 4	Homo sapiens	54-59
30356017-7	2018	Taken together, our results reveal that regulation of HSP70 through K77 acetylation plays role in combined PP242 and curcumin treatment-induced apoptosis.	PP242	107-112	keratin 77	Homo sapiens	68-71
30154246-6	2018	Overexpression of constitutively active Taz (Taz-S89A) could restore fibroblast activation suppressed by PP242, an mTOR kinase inhibitor in NRK-49F cells.	PP242	105-110	tafazzin, phospholipid-lysophospholipid transacylase	Rattus norvegicus	40-43
29849119-3	2018	However, PP242 (inhibitor of mTORC1 and mTORC2) alone did not induce human renal carcinoma cell death.	PP242	9-14	CREB regulated transcription coactivator 1	Mus musculus	29-35
29849119-6	2018	Furthermore, co-treatment with PP242 and curcumin-induced the downregulation of the Rictor (an mTORC2 complex protein) and Akt protein levels, and ectopic overexpression of Rictor or Akt inhibited PP242 plus curcumin induced cell death.	PP242	31-36	RPTOR independent companion of MTOR complex 2	Homo sapiens	84-90
29849119-6	2018	Furthermore, co-treatment with PP242 and curcumin-induced the downregulation of the Rictor (an mTORC2 complex protein) and Akt protein levels, and ectopic overexpression of Rictor or Akt inhibited PP242 plus curcumin induced cell death.	PP242	31-36	CREB regulated transcription coactivator 2	Mus musculus	95-101
29849119-6	2018	Furthermore, co-treatment with PP242 and curcumin-induced the downregulation of the Rictor (an mTORC2 complex protein) and Akt protein levels, and ectopic overexpression of Rictor or Akt inhibited PP242 plus curcumin induced cell death.	PP242	31-36	AKT serine/threonine kinase 1	Homo sapiens	123-126
29849119-6	2018	Furthermore, co-treatment with PP242 and curcumin-induced the downregulation of the Rictor (an mTORC2 complex protein) and Akt protein levels, and ectopic overexpression of Rictor or Akt inhibited PP242 plus curcumin induced cell death.	PP242	31-36	RPTOR independent companion of MTOR complex 2	Homo sapiens	173-179
29849119-6	2018	Furthermore, co-treatment with PP242 and curcumin-induced the downregulation of the Rictor (an mTORC2 complex protein) and Akt protein levels, and ectopic overexpression of Rictor or Akt inhibited PP242 plus curcumin induced cell death.	PP242	31-36	AKT serine/threonine kinase 1	Homo sapiens	183-186
29849119-11	2018	Altogether, our results reveal that combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.	PP242	45-50	RPTOR independent companion of MTOR complex 2	Homo sapiens	147-153
29849119-11	2018	Altogether, our results reveal that combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.	PP242	45-50	AKT serine/threonine kinase 1	Homo sapiens	158-161
30131696-9	2018	The disruption on mTORC2/AKT could be reversed by mTORC2 inducer insulin and promoted by mTORC2 inhibitor PP242.	PP242	106-111	CREB regulated transcription coactivator 2	Mus musculus	18-24
29755672-7	2018	Specific inhibition of mTOR activity through siRNA targeting RICTOR and dual mTOR inhibitor PP242 reduced the MM-ECs angiogenic functions, including cell migration, chemotaxis, adhesion, invasion, in vitro angiogenesis on Matrigel , and cytoskeleton reorganization.	PP242	92-97	mechanistic target of rapamycin kinase	Homo sapiens	23-27
29755672-7	2018	Specific inhibition of mTOR activity through siRNA targeting RICTOR and dual mTOR inhibitor PP242 reduced the MM-ECs angiogenic functions, including cell migration, chemotaxis, adhesion, invasion, in vitro angiogenesis on Matrigel , and cytoskeleton reorganization.	PP242	92-97	mechanistic target of rapamycin kinase	Homo sapiens	77-81
29755672-9	2018	PP242 exhibited a synergistic effect with lenalidomide and bortezomib, suggesting that mTOR inhibition can enhance the anti-angiogenic effect of these drugs.	PP242	0-5	mechanistic target of rapamycin kinase	Homo sapiens	87-91
29755672-10	2018	Data to be shown indicate that mTORC2 is involved in MM angiogenesis, and suggest that the dual mTOR inhibitor PP242 may be useful for the anti-angiogenic management of MM patients.	PP242	111-116	CREB regulated transcription coactivator 2	Mus musculus	31-37
29755672-10	2018	Data to be shown indicate that mTORC2 is involved in MM angiogenesis, and suggest that the dual mTOR inhibitor PP242 may be useful for the anti-angiogenic management of MM patients.	PP242	111-116	mechanistic target of rapamycin kinase	Homo sapiens	31-35
29692710-0	2018	PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT.	PP242	0-5	CREB regulated transcription coactivator 2	Mus musculus	113-119
29692710-0	2018	PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT.	PP242	0-5	AKT serine/threonine kinase 1	Homo sapiens	120-123
29692710-9	2018	In this context, we demonstrate that the novel ATP-competitive mTOR inhibitor PP242 effectively targets both mTORC1 and mTORC2 activation and counteracts cell proliferation via the induction of high autophagy levels, besides reducing cell migration, invasiveness and stemness properties.	PP242	78-83	mechanistic target of rapamycin kinase	Homo sapiens	63-67
29692710-9	2018	In this context, we demonstrate that the novel ATP-competitive mTOR inhibitor PP242 effectively targets both mTORC1 and mTORC2 activation and counteracts cell proliferation via the induction of high autophagy levels, besides reducing cell migration, invasiveness and stemness properties.	PP242	78-83	CREB regulated transcription coactivator 1	Mus musculus	109-115
29692710-9	2018	In this context, we demonstrate that the novel ATP-competitive mTOR inhibitor PP242 effectively targets both mTORC1 and mTORC2 activation and counteracts cell proliferation via the induction of high autophagy levels, besides reducing cell migration, invasiveness and stemness properties.	PP242	78-83	CREB regulated transcription coactivator 2	Mus musculus	120-126
30154246-6	2018	Overexpression of constitutively active Taz (Taz-S89A) could restore fibroblast activation suppressed by PP242, an mTOR kinase inhibitor in NRK-49F cells.	PP242	105-110	tafazzin, phospholipid-lysophospholipid transacylase	Rattus norvegicus	45-49
30154246-6	2018	Overexpression of constitutively active Taz (Taz-S89A) could restore fibroblast activation suppressed by PP242, an mTOR kinase inhibitor in NRK-49F cells.	PP242	105-110	mechanistic target of rapamycin kinase	Mus musculus	115-119
30154246-8	2018	Ablation of Rictor in fibroblasts/pericytes or blockade of mTOR signaling with PP242 attenuated Yap/Taz activation and UUO nephropathy in mice.	PP242	79-84	mechanistic target of rapamycin kinase	Mus musculus	59-63
30154246-8	2018	Ablation of Rictor in fibroblasts/pericytes or blockade of mTOR signaling with PP242 attenuated Yap/Taz activation and UUO nephropathy in mice.	PP242	79-84	yes-associated protein 1	Mus musculus	96-99
30154246-8	2018	Ablation of Rictor in fibroblasts/pericytes or blockade of mTOR signaling with PP242 attenuated Yap/Taz activation and UUO nephropathy in mice.	PP242	79-84	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	100-103
29080085-8	2018	In the present study, we report using pp242 which is a dual mTORC1/C2 blocker in cellular model of tauopathy using LUHMES cell line.	PP242	38-43	CREB regulated transcription coactivator 1	Mus musculus	60-66
29080085-12	2018	The present study suggests the possible use of pp242 as a dual mTOR blocker to treat tauopathy.	PP242	47-52	mechanistic target of rapamycin kinase	Homo sapiens	63-67
29195143-1	2018	PP242 is a second generation novel selective ATP-competitive inhibitor of mTOR that displayed promising anti-cancer activity over several cancer types by inhibiting both the complexes of mTOR (mTORC1 and mTORC2).	PP242	0-5	CREB regulated transcription coactivator 1	Mus musculus	193-199
29344639-2	2018	In the present study, the potency of PP242, a novel dual inhibitor of mTOR complex 1/2 (mTORC1/2), in the suppression of the growth of human lens epithelial cells (HLECs) was investigated.	PP242	37-42	mechanistic target of rapamycin kinase	Homo sapiens	70-74
29344639-2	2018	In the present study, the potency of PP242, a novel dual inhibitor of mTOR complex 1/2 (mTORC1/2), in the suppression of the growth of human lens epithelial cells (HLECs) was investigated.	PP242	37-42	CREB regulated transcription coactivator 2	Mus musculus	88-96
29344639-4	2018	In addition, western blot analysis indicated that PP242 completely inhibited mTORC1 and mTORC2 downstream signaling activities, whereas rapamycin only partially inhibited mTORC1 activity within LECs.	PP242	50-55	CREB regulated transcription coactivator 1	Mus musculus	77-83
29344639-4	2018	In addition, western blot analysis indicated that PP242 completely inhibited mTORC1 and mTORC2 downstream signaling activities, whereas rapamycin only partially inhibited mTORC1 activity within LECs.	PP242	50-55	CREB regulated transcription coactivator 2	Mus musculus	88-94
29195143-1	2018	PP242 is a second generation novel selective ATP-competitive inhibitor of mTOR that displayed promising anti-cancer activity over several cancer types by inhibiting both the complexes of mTOR (mTORC1 and mTORC2).	PP242	0-5	CREB regulated transcription coactivator 2	Mus musculus	204-210
29154199-6	2018	Importantly, UVB treatment perturbs the conversion of microtubule-associated protein 1 light chain 3 (LC3)-I to LC3-II and LC3-II turnover in response to treatment with MTOR inhibitors (Torin 1 and pp242), as well as endoplasmic reticular stress (A23187 and tunicamycin), inositol pathway (L690,330) and autophagy inducers (resveratrol and STF62247).	PP242	198-203	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	102-105
29154199-6	2018	Importantly, UVB treatment perturbs the conversion of microtubule-associated protein 1 light chain 3 (LC3)-I to LC3-II and LC3-II turnover in response to treatment with MTOR inhibitors (Torin 1 and pp242), as well as endoplasmic reticular stress (A23187 and tunicamycin), inositol pathway (L690,330) and autophagy inducers (resveratrol and STF62247).	PP242	198-203	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	112-115
29154199-6	2018	Importantly, UVB treatment perturbs the conversion of microtubule-associated protein 1 light chain 3 (LC3)-I to LC3-II and LC3-II turnover in response to treatment with MTOR inhibitors (Torin 1 and pp242), as well as endoplasmic reticular stress (A23187 and tunicamycin), inositol pathway (L690,330) and autophagy inducers (resveratrol and STF62247).	PP242	198-203	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	112-115
29154199-6	2018	Importantly, UVB treatment perturbs the conversion of microtubule-associated protein 1 light chain 3 (LC3)-I to LC3-II and LC3-II turnover in response to treatment with MTOR inhibitors (Torin 1 and pp242), as well as endoplasmic reticular stress (A23187 and tunicamycin), inositol pathway (L690,330) and autophagy inducers (resveratrol and STF62247).	PP242	198-203	mechanistic target of rapamycin kinase	Homo sapiens	169-173
28679058-5	2017	Treatment with mTOR kinase inhibitor, PP242, at Weeks 6-8 after PH induction suppressed both mTORC1 and mTORC2 in small PAs, but only mTORC1 signaling in RV, preserving basal mTORC2-Akt levels.	PP242	38-43	mechanistic target of rapamycin kinase	Rattus norvegicus	15-19
28679058-5	2017	Treatment with mTOR kinase inhibitor, PP242, at Weeks 6-8 after PH induction suppressed both mTORC1 and mTORC2 in small PAs, but only mTORC1 signaling in RV, preserving basal mTORC2-Akt levels.	PP242	38-43	CREB regulated transcription coactivator 1	Mus musculus	93-99
28679058-5	2017	Treatment with mTOR kinase inhibitor, PP242, at Weeks 6-8 after PH induction suppressed both mTORC1 and mTORC2 in small PAs, but only mTORC1 signaling in RV, preserving basal mTORC2-Akt levels.	PP242	38-43	CREB regulated transcription coactivator 2	Mus musculus	104-110
28679058-5	2017	Treatment with mTOR kinase inhibitor, PP242, at Weeks 6-8 after PH induction suppressed both mTORC1 and mTORC2 in small PAs, but only mTORC1 signaling in RV, preserving basal mTORC2-Akt levels.	PP242	38-43	CREB regulated transcription coactivator 1	Mus musculus	134-140
28679058-5	2017	Treatment with mTOR kinase inhibitor, PP242, at Weeks 6-8 after PH induction suppressed both mTORC1 and mTORC2 in small PAs, but only mTORC1 signaling in RV, preserving basal mTORC2-Akt levels.	PP242	38-43	CREB regulated transcription coactivator 2	Mus musculus	175-181
28679058-5	2017	Treatment with mTOR kinase inhibitor, PP242, at Weeks 6-8 after PH induction suppressed both mTORC1 and mTORC2 in small PAs, but only mTORC1 signaling in RV, preserving basal mTORC2-Akt levels.	PP242	38-43	AKT serine/threonine kinase 1	Rattus norvegicus	182-185
28671713-9	2017	The functional polarization process triggered by ATP-P2X/Y-purinoceptor interaction was also involved in the C5a-induced shape changes, because pretreatment with suramin blocked not only the shape changes but also the subsequent C5a-dependent chemotactic activity.	PP242	53-56	complement C5a receptor 1	Homo sapiens	109-112
28300280-5	2018	Also, PP242, an mTORC1/2 kinase inhibitor, repressed survivin expression, and cell proliferation/viability more potently than rapamycin (mTORC1 inhibitor) in B cells in response to hsBAFF.	PP242	6-11	CREB regulated transcription coactivator 1	Mus musculus	16-22
28671713-9	2017	The functional polarization process triggered by ATP-P2X/Y-purinoceptor interaction was also involved in the C5a-induced shape changes, because pretreatment with suramin blocked not only the shape changes but also the subsequent C5a-dependent chemotactic activity.	PP242	53-56	complement C5a receptor 1	Homo sapiens	229-232
28402933-0	2017	PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.	PP242	146-151	pyruvate dehydrogenase kinase 1	Homo sapiens	0-4
28402933-9	2017	Combining PP242, a dual mTORC1/C2 inhibitor, with GSK-470, had greater antimyeloma activity than either one alone in vitro and in MM xenograft model established in immunodeficient mice.	PP242	10-15	CREB regulated transcription coactivator 1	Mus musculus	24-30
28442344-9	2017	Likewise, inhibiting the PI3K-AKT-mTOR pathway with the ATP-competitive mTOR inhibitor PP242 reduced CD44 protein in SNU-423 and SNU-449 cells without altering CD44 mRNA levels.	PP242	87-92	mechanistic target of rapamycin kinase	Homo sapiens	34-38
28442344-9	2017	Likewise, inhibiting the PI3K-AKT-mTOR pathway with the ATP-competitive mTOR inhibitor PP242 reduced CD44 protein in SNU-423 and SNU-449 cells without altering CD44 mRNA levels.	PP242	87-92	mechanistic target of rapamycin kinase	Homo sapiens	72-76
28442344-9	2017	Likewise, inhibiting the PI3K-AKT-mTOR pathway with the ATP-competitive mTOR inhibitor PP242 reduced CD44 protein in SNU-423 and SNU-449 cells without altering CD44 mRNA levels.	PP242	87-92	CD44 molecule (Indian blood group)	Homo sapiens	101-105
28592067-1	2017	Objective: To establish the acute myeloid leukemia (AML) mouse model, and to preliminarily investigate the efficiency of dasatinib, a tryosine kinase inhibitor, and PP242, an inhibitor of PI3K/Akt/mTOR signaling pathway in the development of AML.	PP242	165-170	thymoma viral proto-oncogene 1	Mus musculus	193-196
28592067-11	2017	Conclusion: Combination of tryosine kinase inhibitor-dasatinib and PI3K/Akt/mTOR signaling pathway inhibitor- PP242 could delay the progression of AML by inducing more leukemia to apoptosis and arrest more leukemia cells in the cell cycle G0 phase, it may be provied a new method for clinical therapy.	PP242	110-115	thymoma viral proto-oncogene 1	Mus musculus	72-75
28592067-11	2017	Conclusion: Combination of tryosine kinase inhibitor-dasatinib and PI3K/Akt/mTOR signaling pathway inhibitor- PP242 could delay the progression of AML by inducing more leukemia to apoptosis and arrest more leukemia cells in the cell cycle G0 phase, it may be provied a new method for clinical therapy.	PP242	110-115	mechanistic target of rapamycin kinase	Mus musculus	76-80
28612529-1	2017	OBJECTIVES: To investigate the anti-leukemia effect and mechanism of mTORC1/2 inhibitor PP242 combined with imatinib (IM) on the proliferation of Ph+ acute lymphoblastic leukemia (ALL) cell line SUP-B15.	PP242	88-93	CREB regulated transcription coactivator 2	Mus musculus	69-77
28612529-6	2017	CONCLUSION: The combination of IM and PP242 could increase the inhibition of PI3K/Akt/mTOR signaling pathway and apoptosis mediated by bax and caspase-3 in SUP-B15 cell line.	PP242	38-43	AKT serine/threonine kinase 1	Homo sapiens	82-85
28612529-6	2017	CONCLUSION: The combination of IM and PP242 could increase the inhibition of PI3K/Akt/mTOR signaling pathway and apoptosis mediated by bax and caspase-3 in SUP-B15 cell line.	PP242	38-43	mechanistic target of rapamycin kinase	Homo sapiens	86-90
28612529-6	2017	CONCLUSION: The combination of IM and PP242 could increase the inhibition of PI3K/Akt/mTOR signaling pathway and apoptosis mediated by bax and caspase-3 in SUP-B15 cell line.	PP242	38-43	BCL2 associated X, apoptosis regulator	Homo sapiens	135-138
28612529-6	2017	CONCLUSION: The combination of IM and PP242 could increase the inhibition of PI3K/Akt/mTOR signaling pathway and apoptosis mediated by bax and caspase-3 in SUP-B15 cell line.	PP242	38-43	caspase 3	Homo sapiens	143-152
28106723-7	2017	Moreover, both qualitative and quantitative method confirmed the increase of lysosomal pH, and mammalian target of rapamycin (mTOR) inhibitor PP242 treatment relieved this elevation.	PP242	142-147	mechanistic target of rapamycin kinase	Homo sapiens	95-124
28106723-7	2017	Moreover, both qualitative and quantitative method confirmed the increase of lysosomal pH, and mammalian target of rapamycin (mTOR) inhibitor PP242 treatment relieved this elevation.	PP242	142-147	mechanistic target of rapamycin kinase	Homo sapiens	126-130
28106723-8	2017	Moreover, PP242 treatment also alleviated the change of autophagy flux, TER, and claudin-2 expression induced by TNF-alpha.	PP242	10-15	claudin 2	Homo sapiens	81-90
28106723-8	2017	Moreover, PP242 treatment also alleviated the change of autophagy flux, TER, and claudin-2 expression induced by TNF-alpha.	PP242	10-15	tumor necrosis factor	Homo sapiens	113-122
28400912-9	2017	Finally, MTOR inhibition by Rapamycin, everolimus, or pp242 did not affect the series of biological events in keratinocytes exposed to UVB, including the downregulation of BiP and PERK, activation of Histone H2A and JNK, and cleavage of caspase-3 and PARP.	PP242	54-59	mechanistic target of rapamycin kinase	Homo sapiens	9-13
27566137-7	2016	Treatment with rapamycin and PP242, that target the PI3K/AKT/mTOR signaling pathway, modified starvation-induced autophagy and apoptosis in IPF fibroblasts.	PP242	29-34	AKT serine/threonine kinase 1	Homo sapiens	57-60
27566137-7	2016	Treatment with rapamycin and PP242, that target the PI3K/AKT/mTOR signaling pathway, modified starvation-induced autophagy and apoptosis in IPF fibroblasts.	PP242	29-34	mechanistic target of rapamycin kinase	Homo sapiens	61-65
26891668-7	2016	In addition, PP242, a mammalian target rapamycin (mTOR) inhibitor, was used to study the involvement of the mTOR pathway in DADS-induced apoptosis and autophagy.	PP242	13-18	mechanistic target of rapamycin kinase	Homo sapiens	50-54
26894601-3	2016	However, ovarian cancer cells are resistant to PP242, a dual inhibitor of mTORC1 and mTORC2.	PP242	47-52	CREB regulated transcription coactivator 1	Mus musculus	74-80
26894601-3	2016	However, ovarian cancer cells are resistant to PP242, a dual inhibitor of mTORC1 and mTORC2.	PP242	47-52	CREB regulated transcription coactivator 2	Mus musculus	85-91
26894601-4	2016	Interestingly, blockage of GLS1 with a selective inhibitor, CB839, or siRNA dramatically sensitized the PP242-induced cell death, as evident from increased PARP cleavage.	PP242	104-109	glutaminase	Homo sapiens	27-31
26894601-4	2016	Interestingly, blockage of GLS1 with a selective inhibitor, CB839, or siRNA dramatically sensitized the PP242-induced cell death, as evident from increased PARP cleavage.	PP242	104-109	collagen type XI alpha 2 chain	Homo sapiens	156-160
26894601-5	2016	The anti-cancer activity of CB-839 and PP242 was abrogated by the addition of the TCA cycle product alpha-ketoglutarate, indicating the critical function of GLS1 in ovarian cancer cell survival.	PP242	39-44	glutaminase	Homo sapiens	157-161
26894601-6	2016	Finally, glutaminolysis inhibition activated apoptosis and synergistically sensitized ovarian cancer cells to priming with the mTOR inhibitor PP242.	PP242	142-147	mechanistic target of rapamycin kinase	Homo sapiens	127-131
27226604-4	2016	Here we demonstrate that C11 also blocks cyclin D1 IRES-dependent initiation and demonstrates synergistic anti-GBM properties when combined with the mechanistic target of rapamycin kinase inhibitor PP242.	PP242	198-203	mechanistic target of rapamycin kinase	Mus musculus	149-180
27196780-4	2016	We show that platinum-resistant OVCAR-3 ovarian cancer cells are resensitized to low levels of carboplatin in culture by mTOR inhibition, demonstrating reduced survival after treatment with either mTORC1 inhibitor everolimus or mTORC1/2 inhibitor PP242.	PP242	247-252	CREB regulated transcription coactivator 2	Mus musculus	228-236
27358039-2	2016	Here, we report that the dual mTORC1/2 inhibitors PP242 and OSI-027 decreased cell viability but did not induce apoptosis in the non-small cell lung cancer (NSCLC) cell lines H460 and A549.	PP242	50-55	CREB regulated transcription coactivator 1	Mus musculus	30-36
27358039-4	2016	JNK was activated by PP242, and PP242-induced autophagy was blocked by inhibiting JNK pathway with SP600125 or JNK siRNA, suggesting that JNK activation is required for the mTORC1/2 inhibitor-mediated induction of autophagy in NSCLC cells.	PP242	21-26	mitogen-activated protein kinase 8	Homo sapiens	0-3
27358039-4	2016	JNK was activated by PP242, and PP242-induced autophagy was blocked by inhibiting JNK pathway with SP600125 or JNK siRNA, suggesting that JNK activation is required for the mTORC1/2 inhibitor-mediated induction of autophagy in NSCLC cells.	PP242	32-37	mitogen-activated protein kinase 8	Homo sapiens	82-85
27358039-4	2016	JNK was activated by PP242, and PP242-induced autophagy was blocked by inhibiting JNK pathway with SP600125 or JNK siRNA, suggesting that JNK activation is required for the mTORC1/2 inhibitor-mediated induction of autophagy in NSCLC cells.	PP242	32-37	mitogen-activated protein kinase 8	Homo sapiens	82-85
27358039-4	2016	JNK was activated by PP242, and PP242-induced autophagy was blocked by inhibiting JNK pathway with SP600125 or JNK siRNA, suggesting that JNK activation is required for the mTORC1/2 inhibitor-mediated induction of autophagy in NSCLC cells.	PP242	32-37	mitogen-activated protein kinase 8	Homo sapiens	82-85
27358039-4	2016	JNK was activated by PP242, and PP242-induced autophagy was blocked by inhibiting JNK pathway with SP600125 or JNK siRNA, suggesting that JNK activation is required for the mTORC1/2 inhibitor-mediated induction of autophagy in NSCLC cells.	PP242	32-37	CREB regulated transcription coactivator 2	Mus musculus	173-181
26956871-7	2016	Mutated MTOR identified in CNS GCTs upregulated phosphorylation of the AKT pathway proteins including AKT and 4EBP1 in nutrient-deprived conditions and enhanced soft-agar colony formation; both events were suppressed in a dose-dependent manner by addition of the MTOR inhibitor pp242.	PP242	278-283	mechanistic target of rapamycin kinase	Homo sapiens	8-12
26956871-7	2016	Mutated MTOR identified in CNS GCTs upregulated phosphorylation of the AKT pathway proteins including AKT and 4EBP1 in nutrient-deprived conditions and enhanced soft-agar colony formation; both events were suppressed in a dose-dependent manner by addition of the MTOR inhibitor pp242.	PP242	278-283	AKT serine/threonine kinase 1	Homo sapiens	71-74
26956871-7	2016	Mutated MTOR identified in CNS GCTs upregulated phosphorylation of the AKT pathway proteins including AKT and 4EBP1 in nutrient-deprived conditions and enhanced soft-agar colony formation; both events were suppressed in a dose-dependent manner by addition of the MTOR inhibitor pp242.	PP242	278-283	AKT serine/threonine kinase 1	Homo sapiens	102-115
26956871-7	2016	Mutated MTOR identified in CNS GCTs upregulated phosphorylation of the AKT pathway proteins including AKT and 4EBP1 in nutrient-deprived conditions and enhanced soft-agar colony formation; both events were suppressed in a dose-dependent manner by addition of the MTOR inhibitor pp242.	PP242	278-283	mechanistic target of rapamycin kinase	Homo sapiens	263-267
26940200-4	2016	In this study, we demonstrate that mTOR inhibitors-rapamycin (RAP), temisirolimus (TEM), torin-1 (TOR) and PP242 suppress invasion and migration induced by Tumor Necrosis Factor-alpha (TNFalpha) and tumor promoter, Phorbol 12-myristate 13-acetate (PMA) and also reduce the expression of the TNFalpha and IL1beta suggesting their potential to regulate factors in microenvironment that support tumor progression.	PP242	107-112	tumor necrosis factor	Homo sapiens	156-183
26984042-8	2016	The mTOR inhibitor PP242, metformin, and DMSO reverted EMT to different extent and through different pathways, depending on the cell lines.	PP242	19-24	mechanistic target of rapamycin kinase	Homo sapiens	4-8
26940200-4	2016	In this study, we demonstrate that mTOR inhibitors-rapamycin (RAP), temisirolimus (TEM), torin-1 (TOR) and PP242 suppress invasion and migration induced by Tumor Necrosis Factor-alpha (TNFalpha) and tumor promoter, Phorbol 12-myristate 13-acetate (PMA) and also reduce the expression of the TNFalpha and IL1beta suggesting their potential to regulate factors in microenvironment that support tumor progression.	PP242	107-112	mechanistic target of rapamycin kinase	Homo sapiens	35-39
26940200-4	2016	In this study, we demonstrate that mTOR inhibitors-rapamycin (RAP), temisirolimus (TEM), torin-1 (TOR) and PP242 suppress invasion and migration induced by Tumor Necrosis Factor-alpha (TNFalpha) and tumor promoter, Phorbol 12-myristate 13-acetate (PMA) and also reduce the expression of the TNFalpha and IL1beta suggesting their potential to regulate factors in microenvironment that support tumor progression.	PP242	107-112	tumor necrosis factor	Homo sapiens	185-193
26940200-4	2016	In this study, we demonstrate that mTOR inhibitors-rapamycin (RAP), temisirolimus (TEM), torin-1 (TOR) and PP242 suppress invasion and migration induced by Tumor Necrosis Factor-alpha (TNFalpha) and tumor promoter, Phorbol 12-myristate 13-acetate (PMA) and also reduce the expression of the TNFalpha and IL1beta suggesting their potential to regulate factors in microenvironment that support tumor progression.	PP242	107-112	tumor necrosis factor	Homo sapiens	291-299
26940200-4	2016	In this study, we demonstrate that mTOR inhibitors-rapamycin (RAP), temisirolimus (TEM), torin-1 (TOR) and PP242 suppress invasion and migration induced by Tumor Necrosis Factor-alpha (TNFalpha) and tumor promoter, Phorbol 12-myristate 13-acetate (PMA) and also reduce the expression of the TNFalpha and IL1beta suggesting their potential to regulate factors in microenvironment that support tumor progression.	PP242	107-112	interleukin 1 beta	Homo sapiens	304-311
26776341-6	2016	Rapamycin and PP242 inhibit phosphorylation of Akt, ribosomal S6 kinase, 4EBP1 and mTOR.	PP242	14-19	AKT serine/threonine kinase 1	Homo sapiens	47-50
26719046-5	2016	Herein, we provide evidence that the combined inhibition of mTORC1/2, using the ATP-competitive binding inhibitor PP242, would effectively suppress GBM growth and dissemination as compared to an allosteric binding inhibitor of mTOR.	PP242	114-119	CREB regulated transcription coactivator 2	Mus musculus	60-68
26719046-5	2016	Herein, we provide evidence that the combined inhibition of mTORC1/2, using the ATP-competitive binding inhibitor PP242, would effectively suppress GBM growth and dissemination as compared to an allosteric binding inhibitor of mTOR.	PP242	114-119	mechanistic target of rapamycin kinase	Homo sapiens	60-64
26719046-6	2016	GBM cells treated with PP242 demonstrated significantly decreased activation of mTORC1 and mTORC2, as shown by reduced phosphorylation of their substrate levels, p70 S6K(Thr389) and AKT(Ser473), respectively, in a dose-dependent manner.	PP242	23-28	CREB regulated transcription coactivator 1	Mus musculus	80-86
26719046-6	2016	GBM cells treated with PP242 demonstrated significantly decreased activation of mTORC1 and mTORC2, as shown by reduced phosphorylation of their substrate levels, p70 S6K(Thr389) and AKT(Ser473), respectively, in a dose-dependent manner.	PP242	23-28	CREB regulated transcription coactivator 2	Mus musculus	91-97
26719046-6	2016	GBM cells treated with PP242 demonstrated significantly decreased activation of mTORC1 and mTORC2, as shown by reduced phosphorylation of their substrate levels, p70 S6K(Thr389) and AKT(Ser473), respectively, in a dose-dependent manner.	PP242	23-28	ubiquitin associated and SH3 domain containing B	Homo sapiens	162-165
26719046-7	2016	Furthermore, insulin induced activation of these kinases was abrogated by pretreatment with PP242 as compared with rapamycin.	PP242	92-97	insulin	Homo sapiens	13-20
26719046-8	2016	Unlike rapamycin, PP242 modestly activates extracellular regulated kinase (ERK1/2), as shown by expression of pERK(Thr202/Tyr204).	PP242	18-23	mitogen-activated protein kinase 3	Homo sapiens	75-81
26719046-8	2016	Unlike rapamycin, PP242 modestly activates extracellular regulated kinase (ERK1/2), as shown by expression of pERK(Thr202/Tyr204).	PP242	18-23	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	110-114
26719046-11	2016	In conclusion, these results underscore the potential therapeutic use of the PP242, a novel ATP-competitive binding inhibitor of mTORC1/2 kinase, in suppression of GBM growth and dissemination.	PP242	77-82	CREB regulated transcription coactivator 1	Mus musculus	129-135
26163195-5	2016	The mTOR catalytic site inhibitor, PP242, but not mTORC1 inhibitor rapamycin, inhibits ENaC, decreases Na(+) flux in isolated perfused tubules and induces natriuresis in wild-type mice.	PP242	35-40	mechanistic target of rapamycin kinase	Mus musculus	4-8
26163195-5	2016	The mTOR catalytic site inhibitor, PP242, but not mTORC1 inhibitor rapamycin, inhibits ENaC, decreases Na(+) flux in isolated perfused tubules and induces natriuresis in wild-type mice.	PP242	35-40	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	87-91
26548560-0	2016	PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2/AKT1 signaling pathway.	PP242	0-5	AKT serine/threonine kinase 1	Homo sapiens	130-134
26548560-2	2016	The present study assessed the effects of mTORC2 inhibitor PP242 on the proliferation and migration of bladder cancer cells by using Cell Counting Kit-8, 5-ethynyl-2"-deoxyuridine incorporation, wound healing and Transwell assays.	PP242	59-64	CREB regulated transcription coactivator 2	Mus musculus	42-48
26548560-6	2016	In addition, PP242 markedly restrained the phosphorylation of AKT1 and mTORC2, while the phosphorylation status of S6K1 and mTORC1 was not affected.	PP242	13-18	AKT serine/threonine kinase 1	Homo sapiens	62-66
26548560-6	2016	In addition, PP242 markedly restrained the phosphorylation of AKT1 and mTORC2, while the phosphorylation status of S6K1 and mTORC1 was not affected.	PP242	13-18	CREB regulated transcription coactivator 2	Mus musculus	71-77
26548560-7	2016	These results suggested that PP242 exerts potent inhibitory effects on bladder cancer cells by modulating the activity of the mTORC2/AKT1 pathway.	PP242	29-34	CREB regulated transcription coactivator 2	Mus musculus	126-132
26548560-7	2016	These results suggested that PP242 exerts potent inhibitory effects on bladder cancer cells by modulating the activity of the mTORC2/AKT1 pathway.	PP242	29-34	AKT serine/threonine kinase 1	Homo sapiens	133-137
26776341-6	2016	Rapamycin and PP242 inhibit phosphorylation of Akt, ribosomal S6 kinase, 4EBP1 and mTOR.	PP242	14-19	mechanistic target of rapamycin kinase	Homo sapiens	83-87
30188618-1	2016	pp242, a TORC1/C2 kinase inhibitor, was used as a trigger of cell autophagy.	PP242	0-5	CREB regulated transcription coactivator 1	Rattus norvegicus	9-14
30188621-0	2016	CHLOROQUINE DOES NOT CANCEL E1A+cHa-Ras TRANSFORMANTS" DEATH INDUCED BY mTOR KINASE INHIBITOR pp242.	PP242	94-99	mechanistic target of rapamycin kinase	Rattus norvegicus	72-76
30188621-2	2016	pp242, a TORC1/C2 kinase inhibitor, was used as a trigger of cell autophagy.	PP242	0-5	CREB regulated transcription coactivator 1	Rattus norvegicus	9-14
26636543-0	2015	mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cells.	PP242	22-27	mechanistic target of rapamycin kinase	Homo sapiens	0-4
26636543-6	2015	The ATP-competitive mTORC1/mTORC2 kinase inhibitor pp242 is highly cytotoxic by suppressing the function of mTORC1-4EBP1 axis and mTORC1-dependent phosphorylation of mTORC1 target--ULK1-Ser757 (Atg1).	PP242	51-56	CREB regulated transcription coactivator 1	Mus musculus	20-26
26636543-6	2015	The ATP-competitive mTORC1/mTORC2 kinase inhibitor pp242 is highly cytotoxic by suppressing the function of mTORC1-4EBP1 axis and mTORC1-dependent phosphorylation of mTORC1 target--ULK1-Ser757 (Atg1).	PP242	51-56	CREB regulated transcription coactivator 2	Mus musculus	27-33
26636543-6	2015	The ATP-competitive mTORC1/mTORC2 kinase inhibitor pp242 is highly cytotoxic by suppressing the function of mTORC1-4EBP1 axis and mTORC1-dependent phosphorylation of mTORC1 target--ULK1-Ser757 (Atg1).	PP242	51-56	CREB regulated transcription coactivator 1	Mus musculus	108-114
26636543-6	2015	The ATP-competitive mTORC1/mTORC2 kinase inhibitor pp242 is highly cytotoxic by suppressing the function of mTORC1-4EBP1 axis and mTORC1-dependent phosphorylation of mTORC1 target--ULK1-Ser757 (Atg1).	PP242	51-56	CREB regulated transcription coactivator 1	Mus musculus	108-114
26636543-6	2015	The ATP-competitive mTORC1/mTORC2 kinase inhibitor pp242 is highly cytotoxic by suppressing the function of mTORC1-4EBP1 axis and mTORC1-dependent phosphorylation of mTORC1 target--ULK1-Ser757 (Atg1).	PP242	51-56	CREB regulated transcription coactivator 1	Mus musculus	108-114
26636543-6	2015	The ATP-competitive mTORC1/mTORC2 kinase inhibitor pp242 is highly cytotoxic by suppressing the function of mTORC1-4EBP1 axis and mTORC1-dependent phosphorylation of mTORC1 target--ULK1-Ser757 (Atg1).	PP242	51-56	unc-51 like autophagy activating kinase 1	Homo sapiens	181-185
26636543-6	2015	The ATP-competitive mTORC1/mTORC2 kinase inhibitor pp242 is highly cytotoxic by suppressing the function of mTORC1-4EBP1 axis and mTORC1-dependent phosphorylation of mTORC1 target--ULK1-Ser757 (Atg1).	PP242	51-56	unc-51 like autophagy activating kinase 1	Homo sapiens	194-198
26636543-10	2015	According to transmission electron microscopy data, short-term pp242-treated ERas cells exhibit numerous heavily damaged mitochondria, which are included in single membrane-bound autophagic/autolysophagic vacuoles (mitophagy).	PP242	63-68	ES cell expressed Ras	Homo sapiens	77-81
26885449-3	2015	The effect of metformin alone or in combination with pp242 (an mTOR inhibitor) on salivary adenocarcinoma cells growth were determined in vitro and in vivo.	PP242	53-58	mechanistic target of rapamycin kinase	Homo sapiens	63-67
26885449-6	2015	The distinctive effects of metformin and PP242 on MYC reduction and P53 restoration suggested that metformin inhibited cell growth through a different pathway from PP242 in salivary carcinoma cells.	PP242	41-46	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	50-53
26586952-2	2015	On the other hand, although the second-generation mTOR inhibitor, PP242, has exerted substantial efficacy, it was revealed that independent inhibition by PP242 was transient, which could lead to positive-feedback loop to EGFR.	PP242	66-71	mechanistic target of rapamycin kinase	Homo sapiens	50-54
26586952-2	2015	On the other hand, although the second-generation mTOR inhibitor, PP242, has exerted substantial efficacy, it was revealed that independent inhibition by PP242 was transient, which could lead to positive-feedback loop to EGFR.	PP242	66-71	epidermal growth factor receptor	Homo sapiens	221-225
26586952-2	2015	On the other hand, although the second-generation mTOR inhibitor, PP242, has exerted substantial efficacy, it was revealed that independent inhibition by PP242 was transient, which could lead to positive-feedback loop to EGFR.	PP242	154-159	mechanistic target of rapamycin kinase	Homo sapiens	50-54
26586952-2	2015	On the other hand, although the second-generation mTOR inhibitor, PP242, has exerted substantial efficacy, it was revealed that independent inhibition by PP242 was transient, which could lead to positive-feedback loop to EGFR.	PP242	154-159	epidermal growth factor receptor	Homo sapiens	221-225
26586952-6	2015	Interestingly, the percentage of CD44-positive cancer cells was substantially decreased by the combination therapy in comparison with PP242 alone through fluorescence-activated cell sorting.	PP242	134-139	CD44 molecule (Indian blood group)	Homo sapiens	33-37
26416965-5	2015	Blocking mTOR signaling with rapamycin or PP242 or mitochondrial ATP production (e.g., with CCCP) reduced mitochondrial Ca(2+) uptake and membrane potential, and impaired cellular ATP release and neutrophil chemotaxis.	PP242	42-47	mechanistic target of rapamycin kinase	Homo sapiens	9-13
26041412-5	2015	We inhibited mTOR activity in gSSCs with PP242 and found that MEF2C phosphorylation was decreased and that muscle creatine kinase (MCK) expression was suppressed.	PP242	41-46	mechanistic target of rapamycin kinase	Homo sapiens	13-17
26001614-8	2015	Co-treatment with mammalian target of rapamycin kinase complex 1 (mTORC1) inhibitor PP242, which activated transcription factor EB (TFEB) signaling and lysosome biogenesis, partially rescued the accumulation of alpha-SYN in PC12 cells and midbrain neurons.	PP242	84-89	CREB regulated transcription coactivator 1	Mus musculus	66-72
26134617-16	2015	Upon treatments of RICTOR siRNA or PP242, phosphorylated FLNA levels at the regulatory residue (Ser2152) decreased.	PP242	35-40	RPTOR independent companion of MTOR complex 2	Homo sapiens	19-25
26001614-8	2015	Co-treatment with mammalian target of rapamycin kinase complex 1 (mTORC1) inhibitor PP242, which activated transcription factor EB (TFEB) signaling and lysosome biogenesis, partially rescued the accumulation of alpha-SYN in PC12 cells and midbrain neurons.	PP242	84-89	transcription factor EB	Homo sapiens	107-130
26001614-8	2015	Co-treatment with mammalian target of rapamycin kinase complex 1 (mTORC1) inhibitor PP242, which activated transcription factor EB (TFEB) signaling and lysosome biogenesis, partially rescued the accumulation of alpha-SYN in PC12 cells and midbrain neurons.	PP242	84-89	transcription factor EB	Homo sapiens	132-136
26001614-8	2015	Co-treatment with mammalian target of rapamycin kinase complex 1 (mTORC1) inhibitor PP242, which activated transcription factor EB (TFEB) signaling and lysosome biogenesis, partially rescued the accumulation of alpha-SYN in PC12 cells and midbrain neurons.	PP242	84-89	synuclein alpha	Homo sapiens	211-220
26002467-6	2015	Administration of PP242 or knock-down of eIF4E suppressed RACK1-stimulated collagen 1alpha1 production, proliferation and migration in primary HSCs.	PP242	18-23	receptor for activated C kinase 1	Homo sapiens	58-63
26134617-16	2015	Upon treatments of RICTOR siRNA or PP242, phosphorylated FLNA levels at the regulatory residue (Ser2152) decreased.	PP242	35-40	filamin A	Homo sapiens	57-61
25535978-1	2015	PP242 is a novel dual mammalian target of rapamycin (mTOR) inhibitor that simultaneously inhibits mTORC1 and mTORC2, and its antileukemia effect has been sufficiently investigated here.	PP242	0-5	mechanistic target of rapamycin kinase	Homo sapiens	22-51
25814662-6	2015	At the same time, mTORC1 inhibitors rapamycin and PP242 suppress expression of the Egr1 protein and have an opposite effect on the Egr1 mRNA.	PP242	50-55	CREB regulated transcription coactivator 1	Mus musculus	18-24
25814662-6	2015	At the same time, mTORC1 inhibitors rapamycin and PP242 suppress expression of the Egr1 protein and have an opposite effect on the Egr1 mRNA.	PP242	50-55	early growth response 1	Mus musculus	83-87
25814662-6	2015	At the same time, mTORC1 inhibitors rapamycin and PP242 suppress expression of the Egr1 protein and have an opposite effect on the Egr1 mRNA.	PP242	50-55	early growth response 1	Mus musculus	131-135
25918246-4	2015	Mcl-1 levels in cancer cells were decreased by mTOR kinase inhibitors (TORKinibs), which inhibit both mTORCs, by knocking down rictor and by knocking out rictor or Sin1 but not by silencing raptor.	PP242	71-80	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	0-5
25918246-4	2015	Mcl-1 levels in cancer cells were decreased by mTOR kinase inhibitors (TORKinibs), which inhibit both mTORCs, by knocking down rictor and by knocking out rictor or Sin1 but not by silencing raptor.	PP242	71-80	RPTOR independent companion of MTOR complex 2	Homo sapiens	127-133
25918246-4	2015	Mcl-1 levels in cancer cells were decreased by mTOR kinase inhibitors (TORKinibs), which inhibit both mTORCs, by knocking down rictor and by knocking out rictor or Sin1 but not by silencing raptor.	PP242	71-80	RPTOR independent companion of MTOR complex 2	Homo sapiens	154-160
25918246-4	2015	Mcl-1 levels in cancer cells were decreased by mTOR kinase inhibitors (TORKinibs), which inhibit both mTORCs, by knocking down rictor and by knocking out rictor or Sin1 but not by silencing raptor.	PP242	71-80	MAPK associated protein 1	Homo sapiens	164-168
25918246-6	2015	Moreover, TORKinib-induced Mcl-1 reduction was rescued by proteasome inhibition.	PP242	10-18	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	27-32
25918246-7	2015	Consistently, TORKinib increased Mcl-1 ubiquitination.	PP242	14-22	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	33-38
25918246-9	2015	Suppression of glycogen synthase kinase 3 (GSK3) or FBXW7 rescued Mcl-1 reduction induced by TORKinibs or rictor knockdown.	PP242	93-102	F-box and WD repeat domain containing 7	Homo sapiens	52-57
25918246-9	2015	Suppression of glycogen synthase kinase 3 (GSK3) or FBXW7 rescued Mcl-1 reduction induced by TORKinibs or rictor knockdown.	PP242	93-102	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	66-71
25918246-11	2015	Intriguingly, we detected a direct association between mTORC2 and SCF-FBXW7; this association could be inhibited by TORKinib treatment, suggesting that mTORC2 may directly associate with and inhibit the SCF-FBXW7 complex, resulting in delayed Mcl-1 degradation.	PP242	116-124	CREB regulated transcription coactivator 2	Mus musculus	55-61
25918246-11	2015	Intriguingly, we detected a direct association between mTORC2 and SCF-FBXW7; this association could be inhibited by TORKinib treatment, suggesting that mTORC2 may directly associate with and inhibit the SCF-FBXW7 complex, resulting in delayed Mcl-1 degradation.	PP242	116-124	KIT ligand	Homo sapiens	66-69
25918246-11	2015	Intriguingly, we detected a direct association between mTORC2 and SCF-FBXW7; this association could be inhibited by TORKinib treatment, suggesting that mTORC2 may directly associate with and inhibit the SCF-FBXW7 complex, resulting in delayed Mcl-1 degradation.	PP242	116-124	F-box and WD repeat domain containing 7	Homo sapiens	70-75
25918246-11	2015	Intriguingly, we detected a direct association between mTORC2 and SCF-FBXW7; this association could be inhibited by TORKinib treatment, suggesting that mTORC2 may directly associate with and inhibit the SCF-FBXW7 complex, resulting in delayed Mcl-1 degradation.	PP242	116-124	CREB regulated transcription coactivator 2	Mus musculus	152-158
25918246-11	2015	Intriguingly, we detected a direct association between mTORC2 and SCF-FBXW7; this association could be inhibited by TORKinib treatment, suggesting that mTORC2 may directly associate with and inhibit the SCF-FBXW7 complex, resulting in delayed Mcl-1 degradation.	PP242	116-124	KIT ligand	Homo sapiens	203-206
25918246-11	2015	Intriguingly, we detected a direct association between mTORC2 and SCF-FBXW7; this association could be inhibited by TORKinib treatment, suggesting that mTORC2 may directly associate with and inhibit the SCF-FBXW7 complex, resulting in delayed Mcl-1 degradation.	PP242	116-124	F-box and WD repeat domain containing 7	Homo sapiens	207-212
25918246-11	2015	Intriguingly, we detected a direct association between mTORC2 and SCF-FBXW7; this association could be inhibited by TORKinib treatment, suggesting that mTORC2 may directly associate with and inhibit the SCF-FBXW7 complex, resulting in delayed Mcl-1 degradation.	PP242	116-124	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	243-248
25151963-9	2015	Conversely, suppression of mTOR with the chemical inhibitors PP242 or rapamycin-sensitized DOV13, an ovarian cancer cell line incapable of inducing REDD1, to orlistat-induced cell death through caspase-2.	PP242	61-66	mechanistic target of rapamycin kinase	Homo sapiens	27-31
25762619-5	2015	Also, PP242, an mTORC1/2 kinase inhibitor, inhibited cell adhesion more potently than rapamycin (mTORC1 inhibitor).	PP242	6-11	CREB regulated transcription coactivator 1	Mus musculus	16-22
25535978-1	2015	PP242 is a novel dual mammalian target of rapamycin (mTOR) inhibitor that simultaneously inhibits mTORC1 and mTORC2, and its antileukemia effect has been sufficiently investigated here.	PP242	0-5	mechanistic target of rapamycin kinase	Homo sapiens	53-57
25535978-1	2015	PP242 is a novel dual mammalian target of rapamycin (mTOR) inhibitor that simultaneously inhibits mTORC1 and mTORC2, and its antileukemia effect has been sufficiently investigated here.	PP242	0-5	CREB regulated transcription coactivator 1	Mus musculus	98-104
25535978-1	2015	PP242 is a novel dual mammalian target of rapamycin (mTOR) inhibitor that simultaneously inhibits mTORC1 and mTORC2, and its antileukemia effect has been sufficiently investigated here.	PP242	0-5	CREB regulated transcription coactivator 2	Mus musculus	109-115
25535978-7	2015	The phosphorylation levels of eIF4E (p-eIF4E) at Ser209 influence the antileukemia roles of PP242.	PP242	92-97	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
25535978-7	2015	The phosphorylation levels of eIF4E (p-eIF4E) at Ser209 influence the antileukemia roles of PP242.	PP242	92-97	eukaryotic translation initiation factor 4E	Homo sapiens	37-44
25535978-9	2015	Surprisingly, the effects of PP242 in leukemia cells with high p-eIF4E expression, such as the acute myelomonocytic leukemia THP-1 cell line and M4-M5 primary blasts, were also weak.	PP242	29-34	eukaryotic translation initiation factor 4E	Homo sapiens	63-70
25535978-10	2015	In contrast, PP242 exerted a significant antiproliferative effect in the Ph+ acute lymphoblastic leukemia SUP-B15 cell line and the mantle cell lymphoma JEKO-1 cell line, which had intermediate p-eIF4E levels.	PP242	13-18	eukaryotic translation initiation factor 4E	Homo sapiens	194-201
25535978-11	2015	PP242 inhibited the translation of the antiapoptotic protein Mcl-1 by downregulating the Akt/mTORC1/eIF4E signaling pathway.	PP242	0-5	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	61-66
25535978-11	2015	PP242 inhibited the translation of the antiapoptotic protein Mcl-1 by downregulating the Akt/mTORC1/eIF4E signaling pathway.	PP242	0-5	AKT serine/threonine kinase 1	Homo sapiens	89-92
25535978-11	2015	PP242 inhibited the translation of the antiapoptotic protein Mcl-1 by downregulating the Akt/mTORC1/eIF4E signaling pathway.	PP242	0-5	CREB regulated transcription coactivator 1	Mus musculus	93-99
25535978-11	2015	PP242 inhibited the translation of the antiapoptotic protein Mcl-1 by downregulating the Akt/mTORC1/eIF4E signaling pathway.	PP242	0-5	eukaryotic translation initiation factor 4E	Homo sapiens	100-105
25265063-7	2015	Finally, we testified the role of mTORC2 in vivo by demonstrating that PP242 prevented insulin-stimulated SGK1 activation and ENaC increase during ALI.	PP242	71-76	CREB regulated transcription coactivator 2	Mus musculus	34-40
25265063-7	2015	Finally, we testified the role of mTORC2 in vivo by demonstrating that PP242 prevented insulin-stimulated SGK1 activation and ENaC increase during ALI.	PP242	71-76	insulin	Homo sapiens	87-94
25265063-7	2015	Finally, we testified the role of mTORC2 in vivo by demonstrating that PP242 prevented insulin-stimulated SGK1 activation and ENaC increase during ALI.	PP242	71-76	serum/glucocorticoid regulated kinase 1	Mus musculus	106-110
25415435-4	2015	We found that 2 structurally distinct competitive inhibitors (PP242 and AZD8055), both of which prevent all mTOR-dependent phosphorylation, including that of SGK1, caused substantial natriuresis, but not kaliuresis, in WT mice, which indicates that mTOR preferentially influences ENaC function.	PP242	62-67	mechanistic target of rapamycin kinase	Mus musculus	108-112
25415435-4	2015	We found that 2 structurally distinct competitive inhibitors (PP242 and AZD8055), both of which prevent all mTOR-dependent phosphorylation, including that of SGK1, caused substantial natriuresis, but not kaliuresis, in WT mice, which indicates that mTOR preferentially influences ENaC function.	PP242	62-67	serum/glucocorticoid regulated kinase 1	Mus musculus	158-162
25415435-4	2015	We found that 2 structurally distinct competitive inhibitors (PP242 and AZD8055), both of which prevent all mTOR-dependent phosphorylation, including that of SGK1, caused substantial natriuresis, but not kaliuresis, in WT mice, which indicates that mTOR preferentially influences ENaC function.	PP242	62-67	mechanistic target of rapamycin kinase	Mus musculus	249-253
25239638-4	2015	The aim of the study was to determine the therapeutic effect of an mTOR kinase inhibitor, PP242, in the Han:SPRD rat (Cy/+) model of PKD.	PP242	90-95	mechanistic target of rapamycin kinase	Rattus norvegicus	67-71
25239638-7	2015	On immunoblot of kidneys, PP242 resulted in a decrease in pS6, a marker of mTORC1 signaling and pAkt(Ser473), a marker of mTORC2 signaling.	PP242	26-31	CREB regulated transcription coactivator 1	Mus musculus	75-81
25239638-7	2015	On immunoblot of kidneys, PP242 resulted in a decrease in pS6, a marker of mTORC1 signaling and pAkt(Ser473), a marker of mTORC2 signaling.	PP242	26-31	CREB regulated transcription coactivator 2	Mus musculus	122-128
25440763-0	2015	The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.	PP242	37-42	CREB regulated transcription coactivator 2	Mus musculus	20-26
25440763-1	2015	OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model.	PP242	166-171	mechanistic target of rapamycin kinase	Rattus norvegicus	37-41
25440763-1	2015	OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model.	PP242	166-171	mechanistic target of rapamycin kinase	Rattus norvegicus	82-86
25440763-1	2015	OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model.	PP242	166-171	mechanistic target of rapamycin kinase	Rattus norvegicus	82-86
25440763-1	2015	OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model.	PP242	166-171	CREB regulated transcription coactivator 2	Mus musculus	145-153
25440763-1	2015	OBJECTIVE: To assess the activity of mTOR and downstream effector proteins in the mTOR pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) inhibitor (PP242) compared with that of mTOR complex 1 (mTORC1) inhibitor (rapamycin) using a xenograft tumor model.	PP242	166-171	mechanistic target of rapamycin kinase	Rattus norvegicus	82-86
24949720-12	2014	Importantly, PP242, a specific mTOR inhibitor, abolished both cardioprotection and protein phosphorylation in isolated heart and reduced apoptotic effects in H9c2 cells.	PP242	13-18	mechanistic target of rapamycin kinase	Rattus norvegicus	31-35
25035961-0	2014	PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.	PP242	0-5	AKT serine/threonine kinase 1	Homo sapiens	115-118
25035961-0	2014	PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway.	PP242	0-5	mechanistic target of rapamycin kinase	Homo sapiens	119-123
25035961-9	2014	Then, an inhibitory effect of PP242 on metastasis was observed in gastric cancer cell AGS, along with the cytoskeletal rearrangements and suppression of the phosphorylation of PI3K downstream factors including AKT, mTOR, and P70S6K.	PP242	30-35	AKT serine/threonine kinase 1	Homo sapiens	210-213
25035961-9	2014	Then, an inhibitory effect of PP242 on metastasis was observed in gastric cancer cell AGS, along with the cytoskeletal rearrangements and suppression of the phosphorylation of PI3K downstream factors including AKT, mTOR, and P70S6K.	PP242	30-35	mechanistic target of rapamycin kinase	Homo sapiens	215-219
25035961-9	2014	Then, an inhibitory effect of PP242 on metastasis was observed in gastric cancer cell AGS, along with the cytoskeletal rearrangements and suppression of the phosphorylation of PI3K downstream factors including AKT, mTOR, and P70S6K.	PP242	30-35	ribosomal protein S6 kinase B1	Homo sapiens	225-231
25035961-12	2014	These results show that PP242 suppresses cell proliferation and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway, which might be an effective novel therapeutic candidate against gastric cancer in the future.	PP242	24-29	AKT serine/threonine kinase 1	Homo sapiens	126-129
25035961-12	2014	These results show that PP242 suppresses cell proliferation and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway, which might be an effective novel therapeutic candidate against gastric cancer in the future.	PP242	24-29	mechanistic target of rapamycin kinase	Homo sapiens	130-134
25392452-5	2014	In this report, we use two small molecule inhibitors, PP242 (dual mTOR (mammalian target of rapamycin) kinase inhibitor) and hippuristanol (eIF4A inhibitor), to define IRES regulation via a Bcr-Abl-mTOR-eIF4A axis in CML cell lines and primary patient leukaemias.	PP242	54-59	mechanistic target of rapamycin kinase	Homo sapiens	66-70
25392452-5	2014	In this report, we use two small molecule inhibitors, PP242 (dual mTOR (mammalian target of rapamycin) kinase inhibitor) and hippuristanol (eIF4A inhibitor), to define IRES regulation via a Bcr-Abl-mTOR-eIF4A axis in CML cell lines and primary patient leukaemias.	PP242	54-59	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	190-197
25055139-7	2014	Markers of glutamatergic afferents, VGluT1, and GABAergic afferents, GAD67, were induced by lipopolysaccharides and coexpressed with P2X in small-sized TG neurons.	PP242	133-136	glutamate decarboxylase 1	Rattus norvegicus	69-74
24396066-4	2014	The Paip1-eIF3 interaction is impaired by the mTORC1 inhibitors, rapamycin and PP242.	PP242	79-84	poly(A) binding protein interacting protein 1	Homo sapiens	4-9
23542178-3	2014	We screened a panel of over 600 human cancer cell lines to identify markers of resistance and sensitivity to the mTOR inhibitor PP242.	PP242	128-133	mechanistic target of rapamycin kinase	Homo sapiens	113-117
23542178-7	2014	Immunoblot analysis of the signaling targets downstream of mTOR revealed that the degree of cellular growth inhibition induced by PP242 was correlated with inhibition of phosphorylation of the translational repressor eIF4E-binding protein 1 (4E-BP1), but not ribosomal protein S6 (rpS6).	PP242	130-135	mechanistic target of rapamycin kinase	Homo sapiens	59-63
23542178-7	2014	Immunoblot analysis of the signaling targets downstream of mTOR revealed that the degree of cellular growth inhibition induced by PP242 was correlated with inhibition of phosphorylation of the translational repressor eIF4E-binding protein 1 (4E-BP1), but not ribosomal protein S6 (rpS6).	PP242	130-135	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	217-240
23542178-7	2014	Immunoblot analysis of the signaling targets downstream of mTOR revealed that the degree of cellular growth inhibition induced by PP242 was correlated with inhibition of phosphorylation of the translational repressor eIF4E-binding protein 1 (4E-BP1), but not ribosomal protein S6 (rpS6).	PP242	130-135	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	242-248
23542178-7	2014	Immunoblot analysis of the signaling targets downstream of mTOR revealed that the degree of cellular growth inhibition induced by PP242 was correlated with inhibition of phosphorylation of the translational repressor eIF4E-binding protein 1 (4E-BP1), but not ribosomal protein S6 (rpS6).	PP242	130-135	ribosomal protein S6	Homo sapiens	259-279
23542178-7	2014	Immunoblot analysis of the signaling targets downstream of mTOR revealed that the degree of cellular growth inhibition induced by PP242 was correlated with inhibition of phosphorylation of the translational repressor eIF4E-binding protein 1 (4E-BP1), but not ribosomal protein S6 (rpS6).	PP242	130-135	ribosomal protein S6	Homo sapiens	281-285
24396066-4	2014	The Paip1-eIF3 interaction is impaired by the mTORC1 inhibitors, rapamycin and PP242.	PP242	79-84	eukaryotic translation initiation factor 3 subunit A	Homo sapiens	10-14
24209570-0	2013	Re: Extracellular UDP enhances P2X-mediated bladder smooth muscle contractility via P2Y6 activation of the phospholipase C/Inositol trisphosphate pathway.	PP242	31-34	pyrimidinergic receptor P2Y6	Homo sapiens	84-88
24270265-8	2014	Treatment with the mTOR kinase inhibitor PP242 at days 15 to 28 suppressed mTORC2 but not Nox4, induced smooth muscle-specific apoptosis in small pulmonary arteries, and reversed hypoxia-induced pulmonary vascular remodeling in rats.	PP242	41-46	mechanistic target of rapamycin kinase	Rattus norvegicus	19-23
24270265-8	2014	Treatment with the mTOR kinase inhibitor PP242 at days 15 to 28 suppressed mTORC2 but not Nox4, induced smooth muscle-specific apoptosis in small pulmonary arteries, and reversed hypoxia-induced pulmonary vascular remodeling in rats.	PP242	41-46	CREB regulated transcription coactivator 2	Mus musculus	75-81
24270265-8	2014	Treatment with the mTOR kinase inhibitor PP242 at days 15 to 28 suppressed mTORC2 but not Nox4, induced smooth muscle-specific apoptosis in small pulmonary arteries, and reversed hypoxia-induced pulmonary vascular remodeling in rats.	PP242	41-46	NADPH oxidase 4	Rattus norvegicus	90-94
24316308-3	2014	Using a xenograft tumor model of endometrial cancer, we assessed the activity of mTOR and downstream effector proteins in the mTOR translational control pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) catalytic inhibitor (PP242) compared to that of an allosteric mTOR complex 1 (mTORC1) inhibitor (everolimus, RAD001).	PP242	242-247	mechanistic target of rapamycin kinase	Mus musculus	81-85
24316308-3	2014	Using a xenograft tumor model of endometrial cancer, we assessed the activity of mTOR and downstream effector proteins in the mTOR translational control pathway after treatment with a dual mTOR complex 1 and 2 (mTORC1/2) catalytic inhibitor (PP242) compared to that of an allosteric mTOR complex 1 (mTORC1) inhibitor (everolimus, RAD001).	PP242	242-247	CREB regulated transcription coactivator 2	Mus musculus	211-219
23907312-5	2014	mTOR signaling was activated in stem-like colorectal cancer cells, and mTOR inhibitors (rapamycin and PP242) decreased the capacity of sphere formation as well as ALDH activity.	PP242	102-107	mechanistic target of rapamycin kinase	Homo sapiens	0-4
23907312-5	2014	mTOR signaling was activated in stem-like colorectal cancer cells, and mTOR inhibitors (rapamycin and PP242) decreased the capacity of sphere formation as well as ALDH activity.	PP242	102-107	mechanistic target of rapamycin kinase	Homo sapiens	71-75
25482947-7	2014	Synthetic inhibitors of mTOR (temsirolimus, LY294.002 and PP242) also impaired actinomycin D triggered p53 stabilization and induction of p21.	PP242	58-63	mechanistic target of rapamycin kinase	Homo sapiens	24-28
25482947-7	2014	Synthetic inhibitors of mTOR (temsirolimus, LY294.002 and PP242) also impaired actinomycin D triggered p53 stabilization and induction of p21.	PP242	58-63	tumor protein p53	Homo sapiens	103-106
25482947-7	2014	Synthetic inhibitors of mTOR (temsirolimus, LY294.002 and PP242) also impaired actinomycin D triggered p53 stabilization and induction of p21.	PP242	58-63	H3 histone pseudogene 16	Homo sapiens	138-141
24008673-4	2013	Indeed, inhibition of mTOR pathway by mTOR inhibitors (rapamycin and PP242) or 2DG promoted not only apoptosis but also autophagy in the polyploidy cells induced by Aurora inhibitors.	PP242	69-74	mechanistic target of rapamycin kinase	Homo sapiens	22-26
24008673-4	2013	Indeed, inhibition of mTOR pathway by mTOR inhibitors (rapamycin and PP242) or 2DG promoted not only apoptosis but also autophagy in the polyploidy cells induced by Aurora inhibitors.	PP242	69-74	mechanistic target of rapamycin kinase	Homo sapiens	38-42
23670294-5	2013	Indeed, pharmacological antagonism of Bcl-xL, with ABT-263, combined with PP242-induced activation of BAD markedly augmented apoptosis of CML-BC cell lines and primary CD34(+) progenitors but not those from healthy donors, regardless of drug resistance induced by bone marrow stromal cell-generated signals.	PP242	74-79	CD34 molecule	Homo sapiens	168-172
23838676-3	2013	In the present study, we examined the antitumor effects of a specific mTOR kinase inhibitor, PP242, which blocks both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) pathways, in two ESCC cell lines: Eca-109 and TE-1.	PP242	93-98	mechanistic target of rapamycin kinase	Homo sapiens	70-74
23838676-3	2013	In the present study, we examined the antitumor effects of a specific mTOR kinase inhibitor, PP242, which blocks both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) pathways, in two ESCC cell lines: Eca-109 and TE-1.	PP242	93-98	mechanistic target of rapamycin kinase	Homo sapiens	118-122
23838676-3	2013	In the present study, we examined the antitumor effects of a specific mTOR kinase inhibitor, PP242, which blocks both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) pathways, in two ESCC cell lines: Eca-109 and TE-1.	PP242	93-98	CREB regulated transcription coactivator 1	Mus musculus	134-140
23838676-3	2013	In the present study, we examined the antitumor effects of a specific mTOR kinase inhibitor, PP242, which blocks both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) pathways, in two ESCC cell lines: Eca-109 and TE-1.	PP242	93-98	mechanistic target of rapamycin kinase	Homo sapiens	118-122
23838676-3	2013	In the present study, we examined the antitumor effects of a specific mTOR kinase inhibitor, PP242, which blocks both mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) pathways, in two ESCC cell lines: Eca-109 and TE-1.	PP242	93-98	CREB regulated transcription coactivator 2	Mus musculus	162-168
23838676-4	2013	We showed that PP242, but not rapamycin, attenuated the activities of both mTORC1 and mTORC2 signaling in ESCC.	PP242	15-20	CREB regulated transcription coactivator 1	Mus musculus	75-81
23838676-4	2013	We showed that PP242, but not rapamycin, attenuated the activities of both mTORC1 and mTORC2 signaling in ESCC.	PP242	15-20	CREB regulated transcription coactivator 2	Mus musculus	86-92
23838676-5	2013	PP242 inhibited 4E-binding protein-1 phosphorylation and abrogated mTORC1-dependent PI3K/Akt feedback activation.	PP242	0-5	CREB regulated transcription coactivator 1	Mus musculus	67-73
23838676-5	2013	PP242 inhibited 4E-binding protein-1 phosphorylation and abrogated mTORC1-dependent PI3K/Akt feedback activation.	PP242	0-5	AKT serine/threonine kinase 1	Homo sapiens	89-92
23838676-7	2013	Furthermore, PP242 promoted cisplatin-induced apoptosis and enhanced the antitumor efficacy of cisplatin in ESCC cells, which was likely to be associated with inhibition of Akt activity.	PP242	13-18	AKT serine/threonine kinase 1	Homo sapiens	173-176
23528835-3	2013	Perifosine and PP242, selective inhibitors of Akt and mTORC1/2, respectively, efficiently suppressed the Akt phosphorylation that was induced by the sustained overexpression of Redd1 and increased the sensitivity of the cells to cisplatin.	PP242	15-20	AKT serine/threonine kinase 1	Homo sapiens	46-49
23991179-2	2013	The second generation of mTOR inhibitors such as PP242 targets mTOR kinase; thus, they are capable of inhibiting both mTORC1 and mTORC2.	PP242	49-54	mechanistic target of rapamycin kinase	Homo sapiens	25-29
23991179-2	2013	The second generation of mTOR inhibitors such as PP242 targets mTOR kinase; thus, they are capable of inhibiting both mTORC1 and mTORC2.	PP242	49-54	mechanistic target of rapamycin kinase	Homo sapiens	63-67
23991179-2	2013	The second generation of mTOR inhibitors such as PP242 targets mTOR kinase; thus, they are capable of inhibiting both mTORC1 and mTORC2.	PP242	49-54	CREB regulated transcription coactivator 1	Mus musculus	118-124
23991179-2	2013	The second generation of mTOR inhibitors such as PP242 targets mTOR kinase; thus, they are capable of inhibiting both mTORC1 and mTORC2.	PP242	49-54	CREB regulated transcription coactivator 2	Mus musculus	129-135
23991179-3	2013	To examine the therapeutic potential of the mTOR kinase inhibitors, we treated a panel of colorectal carcinoma cell lines with PP242.	PP242	127-132	mechanistic target of rapamycin kinase	Homo sapiens	44-48
23991179-4	2013	Western blotting showed that the PP242 inhibition of mTORC2-mediated AKT phosphorylation at Ser 473 (AKT(S473)) was transient only in the first few hours of the PP242 treatment.	PP242	33-38	CREB regulated transcription coactivator 2	Mus musculus	53-59
23991179-4	2013	Western blotting showed that the PP242 inhibition of mTORC2-mediated AKT phosphorylation at Ser 473 (AKT(S473)) was transient only in the first few hours of the PP242 treatment.	PP242	33-38	AKT serine/threonine kinase 1	Homo sapiens	69-72
23991179-4	2013	Western blotting showed that the PP242 inhibition of mTORC2-mediated AKT phosphorylation at Ser 473 (AKT(S473)) was transient only in the first few hours of the PP242 treatment.	PP242	33-38	AKT serine/threonine kinase 1	Homo sapiens	101-104
23991179-4	2013	Western blotting showed that the PP242 inhibition of mTORC2-mediated AKT phosphorylation at Ser 473 (AKT(S473)) was transient only in the first few hours of the PP242 treatment.	PP242	161-166	CREB regulated transcription coactivator 2	Mus musculus	53-59
23991179-4	2013	Western blotting showed that the PP242 inhibition of mTORC2-mediated AKT phosphorylation at Ser 473 (AKT(S473)) was transient only in the first few hours of the PP242 treatment.	PP242	161-166	AKT serine/threonine kinase 1	Homo sapiens	69-72
23991179-4	2013	Western blotting showed that the PP242 inhibition of mTORC2-mediated AKT phosphorylation at Ser 473 (AKT(S473)) was transient only in the first few hours of the PP242 treatment.	PP242	161-166	AKT serine/threonine kinase 1	Homo sapiens	101-104
23991179-5	2013	Receptor tyrosine kinase arrays further revealed that PP242 treatment increased the phosphorylated epidermal growth factor receptor (EGFR) at Tyr 1068 (EGFR(T1068)).	PP242	54-59	epidermal growth factor receptor	Homo sapiens	99-131
23991179-5	2013	Receptor tyrosine kinase arrays further revealed that PP242 treatment increased the phosphorylated epidermal growth factor receptor (EGFR) at Tyr 1068 (EGFR(T1068)).	PP242	54-59	epidermal growth factor receptor	Homo sapiens	133-137
23991179-5	2013	Receptor tyrosine kinase arrays further revealed that PP242 treatment increased the phosphorylated epidermal growth factor receptor (EGFR) at Tyr 1068 (EGFR(T1068)).	PP242	54-59	epidermal growth factor receptor	Homo sapiens	152-156
23991179-7	2013	To test this notion, we showed that the combination of PP242 with erlotinib, an EGFR small molecule inhibitor, blocked both mTORC1 and mTORC2 kinase activity.	PP242	55-60	epidermal growth factor receptor	Homo sapiens	80-84
23991179-7	2013	To test this notion, we showed that the combination of PP242 with erlotinib, an EGFR small molecule inhibitor, blocked both mTORC1 and mTORC2 kinase activity.	PP242	55-60	CREB regulated transcription coactivator 1	Mus musculus	124-130
23991179-7	2013	To test this notion, we showed that the combination of PP242 with erlotinib, an EGFR small molecule inhibitor, blocked both mTORC1 and mTORC2 kinase activity.	PP242	55-60	CREB regulated transcription coactivator 2	Mus musculus	135-141
23528835-3	2013	Perifosine and PP242, selective inhibitors of Akt and mTORC1/2, respectively, efficiently suppressed the Akt phosphorylation that was induced by the sustained overexpression of Redd1 and increased the sensitivity of the cells to cisplatin.	PP242	15-20	CREB regulated transcription coactivator 2	Mus musculus	54-62
23528835-3	2013	Perifosine and PP242, selective inhibitors of Akt and mTORC1/2, respectively, efficiently suppressed the Akt phosphorylation that was induced by the sustained overexpression of Redd1 and increased the sensitivity of the cells to cisplatin.	PP242	15-20	AKT serine/threonine kinase 1	Homo sapiens	105-108
23528835-3	2013	Perifosine and PP242, selective inhibitors of Akt and mTORC1/2, respectively, efficiently suppressed the Akt phosphorylation that was induced by the sustained overexpression of Redd1 and increased the sensitivity of the cells to cisplatin.	PP242	15-20	DNA damage inducible transcript 4	Homo sapiens	177-182
23722550-4	2013	Radiation treatment transiently enhanced autophagic flux for a period of 72 hours in these cells and treatment with rapamycin or the mTOR inhibitor PP242 potentiated this effect.	PP242	148-153	mechanistic target of rapamycin kinase	Homo sapiens	133-137
23915343-10	2013	Inhibition of mTOR by PP242 abolished the positive effects of PLD1 on myotubes, whereas modulating PLD influenced the phosphorylation of both S6K1 and Akt, which are respectively substrates of mTORC1 and mTORC2 complexes.	PP242	22-27	mechanistic target of rapamycin kinase	Mus musculus	14-18
23362118-0	2013	Extracellular UDP enhances P2X-mediated bladder smooth muscle contractility via P2Y(6) activation of the phospholipase C/inositol trisphosphate pathway.	PP242	27-30	pyrimidinergic receptor P2Y, G-protein coupled, 6	Mus musculus	80-86
23547259-7	2013	Disrupting formation of SG by inactivation of mTOR with its specific inhibitor pp242 or by depletion of eIF4E or eIF4GI blocks the SG-associated antiapoptotic p21 pathway.	PP242	79-84	mechanistic target of rapamycin kinase	Homo sapiens	46-50
23547259-7	2013	Disrupting formation of SG by inactivation of mTOR with its specific inhibitor pp242 or by depletion of eIF4E or eIF4GI blocks the SG-associated antiapoptotic p21 pathway.	PP242	79-84	H3 histone pseudogene 16	Homo sapiens	159-162
23730416-2	2013	The goal of this study was to compare the radiosensitizing activities of the allosteric mTOR inhibitor rapamycin with that of the competitive mTOR inhibitor PP242.	PP242	157-162	mechanistic target of rapamycin kinase	Homo sapiens	142-146
23147251-5	2013	MATERIALS AND METHODS: We used PP242, a dual inhibitor of mTORC1/mTORC2 and the mTORC1 specific inhibitor rapamycin.	PP242	31-36	CREB regulated transcription coactivator 1	Mus musculus	58-64
23147251-10	2013	In 786-O cells HIF-2alpha inhibition induced by the dual mTORC1/C2 inhibitor PP242 (0.05 to 0.5 mumol/L) resulted in a dose dependent increase in E-cadherin expression and the restored E-cadherin was localized at cell-to-cell junctions.	PP242	77-82	endothelial PAS domain protein 1	Homo sapiens	15-25
23147251-10	2013	In 786-O cells HIF-2alpha inhibition induced by the dual mTORC1/C2 inhibitor PP242 (0.05 to 0.5 mumol/L) resulted in a dose dependent increase in E-cadherin expression and the restored E-cadherin was localized at cell-to-cell junctions.	PP242	77-82	CREB regulated transcription coactivator 1	Mus musculus	57-63
23147251-10	2013	In 786-O cells HIF-2alpha inhibition induced by the dual mTORC1/C2 inhibitor PP242 (0.05 to 0.5 mumol/L) resulted in a dose dependent increase in E-cadherin expression and the restored E-cadherin was localized at cell-to-cell junctions.	PP242	77-82	cadherin 1	Homo sapiens	146-156
23147251-10	2013	In 786-O cells HIF-2alpha inhibition induced by the dual mTORC1/C2 inhibitor PP242 (0.05 to 0.5 mumol/L) resulted in a dose dependent increase in E-cadherin expression and the restored E-cadherin was localized at cell-to-cell junctions.	PP242	77-82	cadherin 1	Homo sapiens	185-195
23319802-4	2013	Using the mTOR kinase inhibitor, PP242, as a research tool, we found that it synergized with TRAIL to augment apoptosis of cancer cells.	PP242	33-38	mechanistic target of rapamycin kinase	Homo sapiens	10-14
23362262-6	2013	Using the mTOR inhibitor PP242, we found that TGFbeta-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression.	PP242	25-30	mechanistic target of rapamycin kinase	Homo sapiens	10-14
23362262-6	2013	Using the mTOR inhibitor PP242, we found that TGFbeta-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression.	PP242	25-30	transforming growth factor beta 1	Homo sapiens	46-53
23362262-6	2013	Using the mTOR inhibitor PP242, we found that TGFbeta-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression.	PP242	25-30	CREB regulated transcription coactivator 1	Homo sapiens	101-106
23362262-6	2013	Using the mTOR inhibitor PP242, we found that TGFbeta-induced both early and sustained activation of TORC1 and TORC2 was necessary for deptor suppression.	PP242	25-30	CREB regulated transcription coactivator 2	Homo sapiens	111-116
23362262-7	2013	PP242-induced reversal of deptor suppression by TGFbeta was associated with a significant inhibition of TGFbeta-stimulated protein synthesis and hypertrophy.	PP242	0-5	transforming growth factor beta 1	Homo sapiens	48-55
23362262-7	2013	PP242-induced reversal of deptor suppression by TGFbeta was associated with a significant inhibition of TGFbeta-stimulated protein synthesis and hypertrophy.	PP242	0-5	transforming growth factor beta 1	Homo sapiens	104-111
23482748-0	2013	Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells.	PP242	23-28	mechanistic target of rapamycin kinase	Homo sapiens	46-50
23482748-1	2013	AIM: PP242 is a compound which inhibits both mammalian target of rapamycin complex-1 (mTORC1) and mTORC2.	PP242	5-10	CREB regulated transcription coactivator 1	Mus musculus	86-92
23482748-1	2013	AIM: PP242 is a compound which inhibits both mammalian target of rapamycin complex-1 (mTORC1) and mTORC2.	PP242	5-10	CREB regulated transcription coactivator 2	Mus musculus	98-104
23319802-4	2013	Using the mTOR kinase inhibitor, PP242, as a research tool, we found that it synergized with TRAIL to augment apoptosis of cancer cells.	PP242	33-38	TNF superfamily member 10	Homo sapiens	93-98
23319802-9	2013	Moreover, knockdown of the E3 ligase Cbl (CBL) abolished PP242-induced FLIP(S) reduction.	PP242	57-62	Cbl proto-oncogene	Homo sapiens	37-40
23319802-9	2013	Moreover, knockdown of the E3 ligase Cbl (CBL) abolished PP242-induced FLIP(S) reduction.	PP242	57-62	Cbl proto-oncogene	Homo sapiens	42-45
23319802-10	2013	Thus, PP242 induces Cbl-dependent degradation of FLIP(S), leading to FLIP(S) downregulation.	PP242	6-11	Cbl proto-oncogene	Homo sapiens	20-23
23533410-5	2013	Mice challenged with p27-VEGF transfected tumor cells were more resistant to the antiangiogenic and apoptotic effects of the rapalog, temsirolimus, and active site mTOR inhibitor, pp242.	PP242	180-185	cyclin-dependent kinase inhibitor 1B	Mus musculus	21-24
23533410-5	2013	Mice challenged with p27-VEGF transfected tumor cells were more resistant to the antiangiogenic and apoptotic effects of the rapalog, temsirolimus, and active site mTOR inhibitor, pp242.	PP242	180-185	vascular endothelial growth factor A	Mus musculus	25-29
23533410-5	2013	Mice challenged with p27-VEGF transfected tumor cells were more resistant to the antiangiogenic and apoptotic effects of the rapalog, temsirolimus, and active site mTOR inhibitor, pp242.	PP242	180-185	mechanistic target of rapamycin kinase	Mus musculus	164-168
23437362-5	2013	Rapamycin caused a striking increase in Akt phosphorylation at Ser(473) while the active-site inhibitors of mTOR (KU63794 and PP242) completely abrogated Akt phosphorylation at this site.	PP242	126-131	mechanistic target of rapamycin kinase	Homo sapiens	108-112
23437362-5	2013	Rapamycin caused a striking increase in Akt phosphorylation at Ser(473) while the active-site inhibitors of mTOR (KU63794 and PP242) completely abrogated Akt phosphorylation at this site.	PP242	126-131	AKT serine/threonine kinase 1	Homo sapiens	154-157
22843885-10	2012	pp242, a novel combined mTORC1/2 inhibitor, and rapamycin limited proliferation by reducing the S-Phase entry as assessed by EdU incorporation, while PDGF increased EdU incorporation.	PP242	0-5	CREB regulated transcription coactivator 2	Mus musculus	24-32
23026799-6	2012	Moreover, inhibition of MTOR by PP242, an inhibitor of MTOR complex1/2, abrogated the changes in both LC3-II and SQSTM1 in AURKA-overexpressing BT-549 cells, suggesting that AURKA-suppressed autophagy might be associated with MTOR activation.	PP242	32-37	mechanistic target of rapamycin kinase	Homo sapiens	24-28
23026799-6	2012	Moreover, inhibition of MTOR by PP242, an inhibitor of MTOR complex1/2, abrogated the changes in both LC3-II and SQSTM1 in AURKA-overexpressing BT-549 cells, suggesting that AURKA-suppressed autophagy might be associated with MTOR activation.	PP242	32-37	mechanistic target of rapamycin kinase	Homo sapiens	55-59
23026799-6	2012	Moreover, inhibition of MTOR by PP242, an inhibitor of MTOR complex1/2, abrogated the changes in both LC3-II and SQSTM1 in AURKA-overexpressing BT-549 cells, suggesting that AURKA-suppressed autophagy might be associated with MTOR activation.	PP242	32-37	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	102-105
23026799-6	2012	Moreover, inhibition of MTOR by PP242, an inhibitor of MTOR complex1/2, abrogated the changes in both LC3-II and SQSTM1 in AURKA-overexpressing BT-549 cells, suggesting that AURKA-suppressed autophagy might be associated with MTOR activation.	PP242	32-37	sequestosome 1	Homo sapiens	113-119
23026799-6	2012	Moreover, inhibition of MTOR by PP242, an inhibitor of MTOR complex1/2, abrogated the changes in both LC3-II and SQSTM1 in AURKA-overexpressing BT-549 cells, suggesting that AURKA-suppressed autophagy might be associated with MTOR activation.	PP242	32-37	aurora kinase A	Homo sapiens	123-128
23026799-6	2012	Moreover, inhibition of MTOR by PP242, an inhibitor of MTOR complex1/2, abrogated the changes in both LC3-II and SQSTM1 in AURKA-overexpressing BT-549 cells, suggesting that AURKA-suppressed autophagy might be associated with MTOR activation.	PP242	32-37	aurora kinase A	Homo sapiens	174-179
23026799-6	2012	Moreover, inhibition of MTOR by PP242, an inhibitor of MTOR complex1/2, abrogated the changes in both LC3-II and SQSTM1 in AURKA-overexpressing BT-549 cells, suggesting that AURKA-suppressed autophagy might be associated with MTOR activation.	PP242	32-37	mechanistic target of rapamycin kinase	Homo sapiens	55-59
22826565-0	2012	Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.	PP242	51-56	CREB regulated transcription coactivator 2	Mus musculus	13-21
22826565-0	2012	Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.	PP242	51-56	mechanistic target of rapamycin kinase	Mus musculus	13-17
22826565-6	2012	Mechanistically, PP242 attenuated the activities of mTORC1 and mTORC2, sequentially inhibited phosphorylated AKT, S6K, and 4EBP1, and concurrently suppressed chemokine receptor CXCR4 expression in primary leukemic cells and in stromal cells cultured alone or cocultured with leukemic cells.	PP242	17-22	CREB regulated transcription coactivator 1	Mus musculus	52-58
22826565-6	2012	Mechanistically, PP242 attenuated the activities of mTORC1 and mTORC2, sequentially inhibited phosphorylated AKT, S6K, and 4EBP1, and concurrently suppressed chemokine receptor CXCR4 expression in primary leukemic cells and in stromal cells cultured alone or cocultured with leukemic cells.	PP242	17-22	CREB regulated transcription coactivator 2	Mus musculus	63-69
22826565-6	2012	Mechanistically, PP242 attenuated the activities of mTORC1 and mTORC2, sequentially inhibited phosphorylated AKT, S6K, and 4EBP1, and concurrently suppressed chemokine receptor CXCR4 expression in primary leukemic cells and in stromal cells cultured alone or cocultured with leukemic cells.	PP242	17-22	thymoma viral proto-oncogene 1	Mus musculus	109-112
22826565-6	2012	Mechanistically, PP242 attenuated the activities of mTORC1 and mTORC2, sequentially inhibited phosphorylated AKT, S6K, and 4EBP1, and concurrently suppressed chemokine receptor CXCR4 expression in primary leukemic cells and in stromal cells cultured alone or cocultured with leukemic cells.	PP242	17-22	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	117-128
22826565-6	2012	Mechanistically, PP242 attenuated the activities of mTORC1 and mTORC2, sequentially inhibited phosphorylated AKT, S6K, and 4EBP1, and concurrently suppressed chemokine receptor CXCR4 expression in primary leukemic cells and in stromal cells cultured alone or cocultured with leukemic cells.	PP242	17-22	chemokine (C-X-C motif) receptor 4	Mus musculus	177-182
22826565-7	2012	In the in vivo leukemia mouse model, PP242 inhibited mTOR signaling in leukemic cells and demonstrated a greater antileukemia effect than rapamycin.	PP242	37-42	mechanistic target of rapamycin kinase	Mus musculus	53-57
22476852-4	2012	We demonstrated that inhibition of mTORC1/2 by mTOR kinase inhibitors PP242 and OSI-027 effectively suppress phosphorylation of Akt (S473) and breast cancer cell proliferation.	PP242	70-75	CREB regulated transcription coactivator 1	Mus musculus	35-41
22476852-4	2012	We demonstrated that inhibition of mTORC1/2 by mTOR kinase inhibitors PP242 and OSI-027 effectively suppress phosphorylation of Akt (S473) and breast cancer cell proliferation.	PP242	70-75	mechanistic target of rapamycin kinase	Homo sapiens	35-39
22476852-4	2012	We demonstrated that inhibition of mTORC1/2 by mTOR kinase inhibitors PP242 and OSI-027 effectively suppress phosphorylation of Akt (S473) and breast cancer cell proliferation.	PP242	70-75	AKT serine/threonine kinase 1	Homo sapiens	128-131
22685175-8	2012	The PI3K/mTOR pathway inhibitors rapamycin, PI103, and PP242 also inhibited activated signal transduction and translational machinery proteins of the PI3K/mTOR pathway, suggesting that signal transduction inhibitors targeting this pathway also may have therapeutic relevance for patients with CRLF2-rearranged ALL and merit further preclinical testing.	PP242	55-60	mechanistic target of rapamycin kinase	Homo sapiens	9-13
22685175-8	2012	The PI3K/mTOR pathway inhibitors rapamycin, PI103, and PP242 also inhibited activated signal transduction and translational machinery proteins of the PI3K/mTOR pathway, suggesting that signal transduction inhibitors targeting this pathway also may have therapeutic relevance for patients with CRLF2-rearranged ALL and merit further preclinical testing.	PP242	55-60	mechanistic target of rapamycin kinase	Homo sapiens	155-159
22685175-8	2012	The PI3K/mTOR pathway inhibitors rapamycin, PI103, and PP242 also inhibited activated signal transduction and translational machinery proteins of the PI3K/mTOR pathway, suggesting that signal transduction inhibitors targeting this pathway also may have therapeutic relevance for patients with CRLF2-rearranged ALL and merit further preclinical testing.	PP242	55-60	cytokine receptor like factor 2	Homo sapiens	293-298
22566604-7	2012	Finally, we show that the mTOR inhibitors rapamycin and pp242 work together with 17-AAG to inhibit leukemia cell growth to a greater extent than either drug alone.	PP242	56-61	mechanistic target of rapamycin kinase	Homo sapiens	26-30
22556409-2	2012	Newer mTOR inhibitors (like pp242) can overcome feedback activation of AKT in multiple myeloma (MM) cells.	PP242	28-33	mechanistic target of rapamycin kinase	Homo sapiens	6-10
22556409-4	2012	PP242 induced ERK activation in MM cell lines as well as primary cells.	PP242	0-5	mitogen-activated protein kinase 1	Homo sapiens	14-17
22556409-10	2012	Furthermore, ectopic expression of eIF-4E blunted pp242-induced ERK phosphorylation.	PP242	50-55	eukaryotic translation initiation factor 4E	Homo sapiens	35-41
22556409-10	2012	Furthermore, ectopic expression of eIF-4E blunted pp242-induced ERK phosphorylation.	PP242	50-55	mitogen-activated protein kinase 1	Homo sapiens	64-67
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	PP242	6-11	eukaryotic translation initiation factor 4E	Homo sapiens	70-76
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	PP242	180-185	eukaryotic translation initiation factor 4E	Homo sapiens	70-76
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	PP242	180-185	CREB regulated transcription coactivator 1	Homo sapiens	80-85
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	PP242	180-185	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	86-92
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	PP242	180-185	eukaryotic translation initiation factor 4E	Homo sapiens	93-99
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	PP242	180-185	mitogen-activated protein kinase 1	Homo sapiens	122-125
22556409-12	2012	Use of MEK inhibitors confirmed ERK activation served as a mechanism of resistance to the lethal effects of pp242.	PP242	108-113	mitogen-activated protein kinase kinase 7	Homo sapiens	7-10
22556409-12	2012	Use of MEK inhibitors confirmed ERK activation served as a mechanism of resistance to the lethal effects of pp242.	PP242	108-113	mitogen-activated protein kinase 1	Homo sapiens	32-35
22927967-11	2012	Furthermore, MHY1485 induced mTOR activation and correspondingly showed a higher docking score than PP242, a well-known ATP-competitive mTOR inhibitor, in docking simulation.	PP242	100-105	mechanistic target of rapamycin kinase	Rattus norvegicus	136-140
22223645-1	2012	An intensive recent effort to develop ATP-competitive mTOR inhibitors has resulted in several potent and selective molecules such as Torin1, PP242, KU63794, and WYE354.	PP242	141-146	mechanistic target of rapamycin kinase	Homo sapiens	54-58
22401294-5	2012	METHODS: LS174T, SW480 and DLD-1 colon cancer cell lines were treated with PP242 an ATP-competitive inhibitor of mTOR, NVP-BEZ235, a dual PI3K/mTOR inhibitor or rapamycin.	PP242	75-80	mechanistic target of rapamycin kinase	Homo sapiens	113-117
22241218-6	2012	Targeting mTORC1/2 with PP242 was also effective, either as a monotherapy or, more generally, in combination with ABT-737.	PP242	24-29	CREB regulated transcription coactivator 1	Mus musculus	10-16
22157018-12	2012	However, transient inhibition of mTORC2 by PP242 completely abolished the phosphorylation of 4EBP1 and decreased basal as well as putrescine-induced AZ1 expression.	PP242	43-48	CREB regulated transcription coactivator 2	Mus musculus	33-39
22157018-12	2012	However, transient inhibition of mTORC2 by PP242 completely abolished the phosphorylation of 4EBP1 and decreased basal as well as putrescine-induced AZ1 expression.	PP242	43-48	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	93-98
22157018-12	2012	However, transient inhibition of mTORC2 by PP242 completely abolished the phosphorylation of 4EBP1 and decreased basal as well as putrescine-induced AZ1 expression.	PP242	43-48	ornithine decarboxylase antizyme 1	Homo sapiens	149-152
21615676-4	2011	Here we report that inhibition of the mammalian target of rapamycin (mTOR) pathway by rapamycin or PP242 enhances the efficiency of reprogramming to induced pluripotent stem cells (iPSCs).	PP242	99-104	mechanistic target of rapamycin kinase	Homo sapiens	38-67
23285076-6	2012	Specific suppression of YB-1 synthesis resulted from inhibition of the mTOR signaling pathway with inhibitor PP242, but not rapamycin.	PP242	109-114	Y-box-binding protein 1	Oryctolagus cuniculus	24-28
23285076-6	2012	Specific suppression of YB-1 synthesis resulted from inhibition of the mTOR signaling pathway with inhibitor PP242, but not rapamycin.	PP242	109-114	serine/threonine-protein kinase mTOR	Oryctolagus cuniculus	71-75
21615676-4	2011	Here we report that inhibition of the mammalian target of rapamycin (mTOR) pathway by rapamycin or PP242 enhances the efficiency of reprogramming to induced pluripotent stem cells (iPSCs).	PP242	99-104	mechanistic target of rapamycin kinase	Homo sapiens	69-73
21876130-5	2011	We show that the ATP-competitive inhibitor PP242, but not rapamycin, significantly down-regulates cholesterol biosynthesis genes in a 4E-BP1-dependent manner in NIH 3T3 cells, whereas S6 kinase 1 is the dominant regulator in hepatocellular carcinoma cells.	PP242	43-48	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	134-140
21876130-6	2011	To identify other rapamycin-resistant transcriptional outputs of mTOR, we compared the expression profiles of NIH 3T3 cells treated with rapamycin versus PP242.	PP242	154-159	mechanistic target of rapamycin kinase	Mus musculus	65-69
21592956-6	2011	In contrast, Akt2 activity was significantly reduced, concurrent with inhibition of PRAS40 phosphorylation, in the presence of PP242 and Torin1.	PP242	127-132	AKT serine/threonine kinase 2	Homo sapiens	13-17
20686120-3	2010	To assess if the mammalian target of rapamycin within the TORC2 complex could be a better target in MM, we tested a new agent, pp242, which prevents activation of TORC2 as well as TORC1.	PP242	127-132	CREB regulated transcription coactivator 2	Homo sapiens	58-63
20861467-10	2010	mTOR overexpression suppressed LPS-induced secretion of IL-6 (P &lt; 0.001), and the mTOR inhibitors rapamycin and PP242 abolished this inhibitory effect of mTOR.	PP242	115-120	mechanistic target of rapamycin kinase	Mus musculus	85-89
20861467-10	2010	mTOR overexpression suppressed LPS-induced secretion of IL-6 (P &lt; 0.001), and the mTOR inhibitors rapamycin and PP242 abolished this inhibitory effect of mTOR.	PP242	115-120	mechanistic target of rapamycin kinase	Mus musculus	85-89
20686120-3	2010	To assess if the mammalian target of rapamycin within the TORC2 complex could be a better target in MM, we tested a new agent, pp242, which prevents activation of TORC2 as well as TORC1.	PP242	127-132	CREB regulated transcription coactivator 2	Homo sapiens	163-168
20686120-3	2010	To assess if the mammalian target of rapamycin within the TORC2 complex could be a better target in MM, we tested a new agent, pp242, which prevents activation of TORC2 as well as TORC1.	PP242	127-132	CREB regulated transcription coactivator 1	Homo sapiens	180-185
20686120-4	2010	Although comparable to rapamycin against phosphorylation of the TORC1 substrates p70S6kinase and 4E-BP-1, pp242 could also inhibit phosphorylation of AKT on serine 473, a TORC2 substrate, while rapamycin was ineffective.	PP242	106-111	CREB regulated transcription coactivator 1	Homo sapiens	64-69
20686120-4	2010	Although comparable to rapamycin against phosphorylation of the TORC1 substrates p70S6kinase and 4E-BP-1, pp242 could also inhibit phosphorylation of AKT on serine 473, a TORC2 substrate, while rapamycin was ineffective.	PP242	106-111	AKT serine/threonine kinase 1	Homo sapiens	150-153
20686120-4	2010	Although comparable to rapamycin against phosphorylation of the TORC1 substrates p70S6kinase and 4E-BP-1, pp242 could also inhibit phosphorylation of AKT on serine 473, a TORC2 substrate, while rapamycin was ineffective.	PP242	106-111	CREB regulated transcription coactivator 2	Homo sapiens	171-176
20072130-3	2010	We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation.	PP242	27-32	mechanistic target of rapamycin kinase	Homo sapiens	69-73
20227039-4	2010	By using an active site inhibitor of mTOR, PP242, we show a marked therapeutic response in rapamycin-resistant tumors.	PP242	43-48	mechanistic target of rapamycin kinase	Homo sapiens	37-41
20227039-5	2010	The therapeutic benefit of PP242 is mediated through inhibition of mTORC1-dependent 4EBP-eIF4E hyperactivation.	PP242	27-32	CREB regulated transcription coactivator 1	Mus musculus	67-73
20227039-5	2010	The therapeutic benefit of PP242 is mediated through inhibition of mTORC1-dependent 4EBP-eIF4E hyperactivation.	PP242	27-32	eukaryotic translation initiation factor 4E	Homo sapiens	89-94
20072130-3	2010	We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation.	PP242	27-32	CREB regulated transcription coactivator 1	Homo sapiens	82-87
20072130-3	2010	We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation.	PP242	27-32	CREB regulated transcription coactivator 2	Homo sapiens	92-97
20072130-3	2010	We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation.	PP242	27-32	CREB regulated transcription coactivator 2	Homo sapiens	124-131
19209957-8	2009	We investigated mTOR signaling in cells and animals with two novel and specific mTOR kinase domain inhibitors (TORKinibs).	PP242	111-120	mechanistic target of rapamycin kinase	Homo sapiens	16-20
19209957-8	2009	We investigated mTOR signaling in cells and animals with two novel and specific mTOR kinase domain inhibitors (TORKinibs).	PP242	111-120	mechanistic target of rapamycin kinase	Homo sapiens	80-84
18602931-9	2009	The pharmacological profile for P2X antagonists to inhibit [3H]A-804598 binding correlated with their ability to block functional activation of P2X7 receptors (r=0.95, P&lt;0.05).	PP242	32-35	purinergic receptor P2X 7	Homo sapiens	144-148